National Lung Cancer Audit Report 2011



Prepared in partnership with:

The Healthcare Quality Improvement Partnership (HQIP) promotes quality in healthcare. HQIP holds commissioning and funding responsibility for the National Lung Cancer Audit and other national clinical audits as part of the National Clinical Audit & Patient Outcomes Programme (NCAPOP).

The NHS Information Centre for Health and Social Care (The NHS IC) is England's central, authoritative source of essential data and statistical information for frontline decision makers in health and social care. The NHS IC managed the publication of the 2010 annual report.

About the Royal College of Physicians; Clinical Effectiveness & Evaluation Unit
The Clinical Effectiveness and Evaluation unit (CEEu) of the Clinical Standards Department at the Royal College of Physicians runs a vibrant programme of projects that aim to improve the quality of health care in line with the best evidence for clinical practice: national comparative clinical audit, the measurement of clinical and patient outcomes, clinical change management and guideline development. The unit is self-funding, securing commissions and grants, often via competitive tendering processes, from numerous organisations including the Department of Health and charities such as the Health Foundation. Associate directors, who are practicing clinicians in their field, lead the relevant projects / programmes in conjunction with the CEEu clinical director and unit manager.All of our work is carried out in collaboration with relevant specialist societies, patient groups and National Health Service bodies.

National Lung Cancer Audit Report 2011

Report for the audit period 2010

Acknowledgements

The NLCA project team, Mick Peake, Paul Beckett, Ian Woolhouse and Roz Stanley, would like to thank all the organisations that have made this report possible. These include The Healthcare Quality Improvement Partnership (HQIP), The Royal College of Physicians (The RCP), The NHS Information Centre (The IC), NHS Connecting for Health (CFH), The University of Nottingham, The Cancer Information System CYMRU (CANISC), Informing Healthcare (Wales), Welsh Cancer Intelligence and Surveillance Unit (WCISU), South-East Scotland Cancer Network (SCAN), North of Scotland Cancer Network (NoSCAN) and West of Scotland Cancer Network (WoSCAN),The Northern Ireland Cancer Patient Pathway System (CaPPS), The Northern Ireland Cancer Network (NICaN) Lung Group, The Northern Ireland Cancer Registry (NICR), funded by the Northern Ireland Public Health Agency (PHA), The Cancer Information Centre Southampton University Hospitals NHS Trust, Rebecca Sherrington, Clinical Nurse Specialist and Dr W. Anees, Consultant Physician, Princess Elizabeth Hospital Guernsey. Thanks must also go to all the lung cancer teams who have contributed data to the audit as without their considerable efforts this report would not be possible.

Purpose

The purpose of this document, the 7th annual report of the National Lung Cancer Audit, is to summarise the key findings of the Audit for patients diagnosed with lung cancer or mesothelioma who were first seen in 2010. The history, purpose and methodology of the audit has been extensively documented and further details can be obtained from the NHS Information Centre website.

Based on the comments of service users we have again produced this short report highlighting key issues. More extensive analyses on the 2010 data, including case-mix adjusted data in an electronic spreadsheet format will be available from the NHS Information Centre website in due course.

Every trust in England and Wales, and every Health Board in Scotland has participated in the audit, although because of differences in reporting schedules, standards and targets the Scottish data are tabulated separately. Northern Ireland and Guernsey have also participated in the audit, and similarly their data has been tabulated separately.

Details of care provided by individual organisation in the report is based on "place first seen" in secondary care. As a result some tertiary centres may appear to have little input into the care of lung cancer and mesothelioma patients and to submit little data to the audit, but on the contrary, they usually provide the most complex care for the most difficult patients and submit treatment data on behalf of other trusts. The audit team is working on ways to report this important activity in the future.

All data presented refers to cases submitted to the National Lung Cancer Audit unless otherwise stated.

Contents

Key messages

- The audit has collected data on 38,057 patients in Great Britain and Northern Ireland for this audit period, representing approximately 93 per cent of the expected number of new lung cancer cases. This is thought to represent almost all cases of lung cancer presenting to secondary care.
- The quality of the submitted data is of a high standard and similar to that seen in the 2010 report, once again allowing detailed comparison of cancer networks and hospital trusts. Collection of high quality data has become embedded practice for most lung cancer teams, but there is still room for improvement particularly in submission of data on Disease Stage and Performance Status in individual cases.
- However, some organisations continue to submit data that indicates suboptimal care. It is not good enough to blame such results on poor quality data - clinical teams need to take more responsibility for the data that is submitted to the audit, since good data is the cornerstone of quality improvement.
- Measures of the standards of care are largely similar to those seen last year, and whilst still below those reported from other Western European countries, the gap is narrowing. Despite these improvements, there remains variation across trusts and networks and differences in case-mix do not appear to explain the whole of this variation. Poor data completeness in a few areas, especially where trusts fall at the lower extreme of these measures, may contribute to some of the variation seen:

1: Percentage of patients receiving a histological / cytological diagnosis

	England and Wales			Scotland			Northern Ireland		Guernsey	
	2010	2009	2008	2010	2009	2008	2010	2009	2010	2009
Mean	76.0	75.6	72.2	77.1	77.7	77.5	75.4	70.8	95.2	n/a
Min	0.0	0.0	0.0	0.0	0.0	56.0	n/a	n/a	n/a	n/a
Lower Quartile	70.5	70.9	66.6	70.0	69.5	71.7	n/a	n/a	n/a	n/a
Median	76.5	77.5	73.3	75.3	76.1	78.5	n/a	n/a	n/a	n/a
Upper Quartile	83.6	85.2	82.1	79.4	81.4	82.1	n/a	n/a	n/a	n/a
Max	100.0	100.0	100.0	100.0	100.0	88.2	n/a	n/a	n/a	n/a

2: Percentage of patients receiving an operation

	England and Wales			Scotland			Northern Ireland		Guernsey	
	2010	2009	2008	2010	2009	2008	2010	2009	2010	2009
Mean	13.7	13.7	10.8	11.1	11.3	10.6	12.3	13.4	11.9	n/a
Min	0.0	0.0	4.0	0.0	0.0	0.0	n/a	n/a	n/a	n/a
Lower Quartile	9.4	9.7	8.1	7.6	7.2	8.0	n/a	n/a	n/a	n/a
Median	13.0	12.4	9.6	9.9	10.0	10.5	n/a	n/a	n/a	n/a
Upper Quartile	17.1	16.1	12.7	11.7	11.5	12.0	n/a	n/a	n/a	n/a
Max	100.0	76.9	24.8	15.8	15.8	16.9	n/a	n/a	n/a	n/a

3: Percentage of patients receiving any active anti cancer treatment rate

	England and Wales			Scotland			Northern Ireland		Guernsey	
	2010	2009	2008	2010	2009	2008	2010	2009	2010	2009
Mean	58.4	59.1	54.0	63.9	64.6	64.1	71.8	64.7	69.0	n/a
Min	0.0	0.0	0.0	0.0	0.0	33.0	n/a	n/a	n/a	n/a
Lower Quartile	52.4	54.0	43.9	57.4	58.0	58.3	n/a	n/a	n/a	n/a
Median	59.8	60.5	54.1	61.6	62.4	62.2	n/a	n/a	n/a	n/a
Upper Quartile	64.8	66.5	61.6	66.8	69.2	67.3	n/a	n/a	n/a	n/a
Max	100.0	100.0	87.8	78.5	83.5	79.5	n/a	n/a	n/a	n/a

4: Percentage receiving CT scan before bronchoscopy

	England and Wales			Scotland			Northern Ireland		Guernsey	
	2010	**2009**	**2008**	**2010**	**2009**	**2008**	**2010**	**2009**	**2010**	**2009**
Mean	84.8	80.7	76.0	92.2	86.4	n/a	83.5	87.2	80.0	n/a
Min	0.0	0.0	0.0	0.0	0.0	n/a	n/a	n/a	n/a	n/a
Lower Quartile	74.4	74.2	64.5	86.3	81.3	n/a	n/a	n/a	n/a	n/a
Median	86.1	82.4	77.8	93.6	83.5	n/a	n/a	n/a	n/a	n/a
Upper Quartile	93.2	91.5	87.0	97.1	91.4	n/a	n/a	n/a	n/a	n/a
Max	100.0	100.0	100.0	100.0	99.3	n/a	n/a	n/a	n/a	n/a

5: Percentage discussed at MDT

	England and Wales			Scotland			Northern Ireland		Guernsey	
	2010	**2009**	**2008**	**2010**	**2009**	**2008**	**2010**	**2009**	**2010**	**2009**
Mean	96.4	94.1	89.0	94.4	95.3	86.1	98.3	91.3	69.0	n/a
Min	66.7	0.0	0.0	0.0	61.5	17.0	n/a	n/a	n/a	n/a
Lower Quartile	94.6	92.2	84.3	86.6	91.5	84.4	n/a	n/a	n/a	n/a
Median	97.6	96.5	93.6	95.6	93.6	90.9	n/a	n/a	n/a	n/a
Upper Quartile	99.2	98.9	97.8	97.1	98.1	95.3	n/a	n/a	n/a	n/a
Max	100.0	100.0	100.0	100.0	100.0	99.2	n/a	n/a	n/a	n/a

- There is good evidence that the audit data has been used in many organisations to drive service improvement and by inference improve the standards of care and patient outcomes. As with the issues over data quality, there remains an urgent need for **all** Cancer Networks and Hospital Trusts to take responsibility for their data and use it to review and improve their local lung cancer services. This report contains a toolkit to help with this process.
- Patients, patient advocates and service commissioners have an important role to play in challenging lung cancer teams to explain and improve their performance.

Recommendations (England and Wales)

1. All hospitals trusts and health boards should participate in this national audit, should submit data on all patients presenting to secondary care diagnosed with either lung cancer or mesothelioma, and should complete all relevant data fields for each individual patient.
2. Data completeness for key fields should exceed 85 per cent and for MDT completeness should exceed 95 per cent (See appendix 2 Local Action Plan).
3. At least 95 per cent of patients submitted to the audit are discussed at a Multidisciplinary Team Meeting.
4. Histological/Cytological Confirmation rates below 75 per cent should be reviewed to determine whether best practice is being followed and whether patients have access to the whole range of biopsy techniques.
5. At least 80 per cent of patients are seen by a lung cancer specialist nurse; at least 80 per cent of patients should have a lung cancer specialist nurse present at the time of diagnosis (note that these data are not available for Wales).
6. For patients undergoing bronchoscopy at least 95 per cent should have a CT scan prior to the procedure.
7. Surgical resection rates for NSCLC below the England and Wales average of 14 per cent should be reviewed. Furthermore for early stage (I and II) disease, rates below 52 per cent should be reviewed to ensure that patient on the margins of operability/resectability are being offered access to specialist thoracic surgical expertise.
8. Active anti-cancer treatment rates below the England and Wales average of 60 per cent should be reviewed.
9. Chemotherapy rates for small cell lung cancer below the England and Wales average of 65 per cent should be reviewed.
10. Chemotherapy rates for good performance status (0-1) stage IIIB / IV NSCLC lung cancer below the England and Wales average of 55 per cent should be reviewed.

A local action planning toolkit is provided at the end of this document to assist organisations in benchmarking against these quality measures. All organisations are encouraged to use the audit data to drive their service development in order to improve the standard of care for lung cancer patients. Trusts whose results in 2010 meet these recommendations should work to maintain their high standards and exceed them where appropriate.

It is important to stress that these quality measures are not targets, since in some cases there will be valid reasons for variation, such as case-mix and patient choice. Where applicable, organisations should take the case-mix adjusted results (published separately) into consideration in the evaluation of their service, although it is noted that in general case-mix does not explain the whole of the variation in practice across organisations.

Performance against these recommendations is highlighted by a system of colour-coding in the data tables.

Scotland

The recommendations do not apply to Scotland, therefore the data in the tables is not colour coded. NHS Quality Improvement Scotland published National Lung Cancer Standards in March 2008 which cover similar items to those above. For example, the Scottish standard for rate of histological/cytological diagnosis is set at a minimum of 75 per cent. Health boards in all Scottish networks will participate in comparing 2010 results measured against these standards.

Northern Ireland

Northern Ireland participated in the audit for the second time this year and in general follow the standards and recommendations for England and Wales.

Summary details of key findings

How many people were diagnosed with lung cancer?

In 2010 there were 32,602 patient records submitted from England and Wales (see figure 1), 4,427 submitted from Scotland (figure 2), 986 submitted from Northern Ireland (figure 3) and 42 submitted form Guernsey (figure 4). Combined, this is approximately 93 per cent of the expected annual incidence and probably almost all of those cases presenting to secondary care (some cases are diagnosed and treated in primary care, or are diagnosed at a post-mortem).

Of these records, 255 were not suitable for further analysis (mainly from the English submissions) as there was no "date first seen" recorded, meaning that it was not possible to be certain that these were cases from 2010. Figures 1, 2, 3 and 4 show the incidence by cancer type.

Figure 1
Number of patient records submitted to the NLCA – England and Wales



Figure 2
Number of patient records submitted to the NLCA – Scotland



Figure 3
Number of patient records submitted to the NLCA – Northern Ireland



Figure 4
Number of patient records submitted to the NLCA – Guernsey



How accurate are the data in this report?

Data submitted to the National Lung Cancer Audit need to be as complete as possible in terms of healthcare organisation participation, population coverage and data field completeness both to ensure the representative nature of the information and to make case-mix adjustment possible. Please refer to previous versions of the Annual Report for a full explanation of this issue.

Healthcare Organisation Participation

Every trust or health board in England and Wales, and every health board in Scotland has participated in the audit. All trusts in Northern Ireland and Princess Elizabeth Hospital Guernsey have also participated in the audit.

Population Coverage

As can be seen from figures 1-4 the audit has captured approximately 93 per cent of the expected number of cases nationally and almost all of those presenting to secondary care. The "Data Completeness" section in table 1a shows the number of cases and per cent of expected cases (based on historic cancer registry returns) submitted by Network and by Trust (key to codes given in the Appendix 1) across England and Wales. Table 1b shows similar data for Scottish networks, 1c for Northern Ireland and 1d for Guernsey. These results were very important in the early days of the audit, but since data submissions reached around 100 per cent of expected (figure 5), they have become less so. However, they can still be useful in interpreting "odd" results in the performance data.

The colour coding in the tables reflects the targets set in the 2009 Local Action Plan (LAP). Note that for case ascertainment (per cent of expected), to achieve green status over 75 per cent of the expected number of cases must have been submitted, trusts attaining 50 – 75 per cent are coded amber whilst trusts submitting less than 50 per cent of the expected number are coded red. Trusts with a high tertiary workload or where the targets are known to not be applicable for other reasons are shown in blue throughout. Many of the trusts in this category fully participate in the audit by submitting treatment data for other trusts. However their full contribution to the audit process may not be reflected by the way these audit data are presented.

Data Field Completeness

Similarly, tables 1a-1d indicate the data completeness for the key non-mandatory fields of Stage and Performance Status (PS) and the data completeness for the MDT discussion indicator and for the recording of treatment. Comparison with previous years (figure 6 for England and Wales) shows that data field completeness continues to improve. In Scotland data completeness shows continued improvement: Stage 90.2 per cent, PS 91.1per cent and MDT 99.4 per cent

Figure 5
Case ascertainment England and Wales

* England only ** England and Wales



Figure 6
Key data field completeness by year

PS Stage * England only ** England and Wales



What is the standard of care given to patients?

Table 2a lists headline indicators (Process, Specialist Nursing, Imaging and Outcome for England and Wales) by Network and by Trust (key to codes given in the Appendix 1) for all lung cancer and mesothelioma cases across England and Wales. These indicators have been chosen to reflect the overall standard of care provided to patients. In interpreting these figures, the above caveats regarding data completeness referred to previously must be borne in mind. Furthermore, the results as presented do not take into account the case-mix of patients. Adjustments to the results to account for case-mix will be available from the NHS Information Centre website in due course. Where applicable, organisations should take the case-mix adjusted results into consideration in the evaluation of their service since although case-mix does not explain the whole of the variation in practice across organisations, it may show a particular result to be, or not to be, a statistical outlier. The colour coding in the tables reflects the targets set in the 2009 Local Action Plan (LAP).

Similar data for Scotland is shown in table 2b. Local Action Plan targets do not apply to Scotland; hence the data are not colour coded. National Lung Cancer Standards published by NHS Quality Improvement Scotland in 2008 include standards for rate of histological confirmation (minimum 75 per cent) and percentage SCLC having chemotherapy (minimum 60 per cent) but do not specify rates of resection or anti-cancer treatment.

Data for Northern Ireland and Guernsey are shown in tables 2c and 2d respectively.

Further details of the changes in the key outputs of the audit are shown in the tables in the "Key Messages" section on page 5. For England and Wales, there has been a further increase to 76 per cent in the proportion of patients receiving a histological/cytological diagnosis, an increase to 96 per cent in the proportion of patients discussed at an MDT, and an increase to almost 85 per cent in the proportion of patients who receive a CT scan prior to a bronchoscopy procedure. The anti-cancer treatment rate and the overall surgical treatment rate have not increased this year, following steady increases in preceding years.

Case-Mix Adjustment

A typical explanation for different audit results from different organisations (hospital trusts or cancer networks) is that there is a different "case-mix". For example, a hospital with a low treatment rate might argue that the patients they treat are older, more socially deprived, have more advanced disease, or poorer fitness (performance status).

The National Lung Cancer Audit collects data that allows such factors to be taken into account. Taking anti-cancer treatment as an example, a statistical technique known as "logistic regression" calculates the likelihood of a patient in an organisation getting treatment compared to a baseline (typically the largest organisation) assuming that patients are matched for their case-mix.

This measure of likelihood of treatment is called an "odds ratio". The baseline organisation will always have an odds ratio of 1.0. If Hospital X has an odds ratio of 0.9, we can say that patients in that hospital are 10 per cent less likely to have treatment (1.0 minus 0.9, converted to a percentage). Odds ratios have a further benefit, in that they provide so-called "confidence intervals", indicating how confident we can be that the observed differences are statistically important.

Case-mix adjusted data in an electronic spreadsheet format will be available from the NHS Information Centre website in due course.

The Lung Cancer Nurse Specialist

There have been improvements in the proportion of patients receiving the input of a lung cancer nurse specialist (LCNS) with the overall figure rising from 64 per cent last year to 75 per cent this year. Likewise the proportion of patients who have the LCNS present at the time they are given their diagnosis has risen from 38 per cent to 48 per cent.

Figure 7 shows that patients seen by a LCNS were more likely to receive anti-cancer treatment compared to those that were not seen or those where no data is recorded (not known whether these patients saw a LCNS). 64.4 per cent of patients seen by a LCNS received anti-cancer treatment compared to 29.8 per cent of those who were not seen by the LCNS. For patients where it was not known whether or not they were seen by a LCNS 44.8 per cent received active treatment. Further statistical analysis demonstrates that this relationship is independent of age, disease stage and performance status.

Figure 7
Proportion of patients seen by LCNS receiving active treatment (England and Wales)

	2010	2009	2008
Seen by LCNS	64.4%	64.8%	59.4%
Data not recorded	44.8%	52.6%	51.0%
Not seen by LCNS	29.8%	30.4%	30.6%

This interesting observation does not, however, imply a "cause and effect" relationship between nursing input and receipt of anti-cancer treatment, and further work, outside the scope of the audit, is needed to investigate this.

Converting data into service improvement

Collecting data is only part of the audit process and it is important that the data is used to improve the services provided to patients and the outcomes of their treatment. There are numerous examples of local organisations doing just this, some working within the Improving Outcomes in Lung Cancer Project ,others working independently within trusts and cancer networks. Furthermore, national organisations such as the National Institute for Health and Clinical Excellence, the British Thoracic Society and the National Cancer Peer Review Programme have all utilised data from the audit in their work programmes for lung cancer. Examples of some of the uses of the audit data are described in the table on page 15:

National Institute for Health and Clinical Excellence (NICE): Guideline development programme	To support the development and health economic assessment of the 2011 update of their 'Guideline on the Management of Lung Cancer'
National Institute for Health and Clinical Excellence (NICE): Quality Standards programme	To support the development of the Quality Standard for Lung Cancer and provide measures for a number of key elements
National Cancer Peer Review Programme (part of the National Cancer Action Team)	To provide data for the 'Clinical Lines of Enquiry' – outcome measures for the assessment of Lung Cancer Multi-Disciplinary Teams in England
Nottingham University – 'LUCADA Fellowship'. Funded by the Royal College of Physicians	An academic MD fellowship based on the use and interpretation of data from the NLCA has resulted in 3 peer-reviewed publications to date
European Respiratory Society Thoracic Oncology Assembly: 'European Initiative for the Quality Management of Lung Cancer'	Underpinning the long term goal of a pan-European comparative audit of lung cancer performance and outcomes
LungPATH – a National Audit and Service Improvement programme in lung cancer pathology in collaboration with Guy's and St Thomas' Hospital and King's College London	A programme, based on the elements of the NLCA that examine the pathological diagnosis of lung cancer, this national audit (funded by an unrestricted educational grant from the pharmaceutical industry) is examining the variations in the quality of the process of the pathological diagnosis of lung cancer and explore factors that explain this variation in England
Society of Cardiothoracic Surgeons, the National Cancer Intelligence Network and Nottingham University	Examining the detail underpinning the variation in surgical resection rates and surgical outcomes for lung cancer patients across the UK
The Health Foundation	Improving Lung Cancer Outcomes - described separately
The Government's 'Transparency Policy'	The NLCA has been chosen as an example of a data source for the initial release of data as the pilot for the Government's Transparency Agenda in December 2011
The Roy Castle Lung Cancer Foundation	Data from the NLCA formed a major part of the report: 'Explaining Variations in Lung Cancer' published by the Roy Castle Lung Cancer Foundation in June 2011
The Department of Health and Cancer Research UK's International Cancer Benchmarking Partnership and the UK Cancer Registries: the collection of staging data on lung cancer	Data on the stage of cancers is essential for the interpretation of variations in cancer survival both within the UK and across national boundaries. The collection of staging data for lung cancer in the NLCA has improved the proportion of patients with stage recorded in the Cancer Registries having significant impact on such initiatives as the International Cancer Benchmarking Partnership
Oxford University Department of Biomedical Engineering	Ph.D. project on clinical decision support and machine learning. The output of the work will be in the form of a clinical decision support platform, intended to act as a software tool to assist the clinicians in coming to informed, timely, safe and effective decisions in lung cancer care.
NHS Atlas of Variation version 2.0, 2011	Data on variation in surgical resection rate derived from the 2009 NLCA are being included in the 2nd edition of the NHS Atlas of Variation. This is part of a wider programme of trying to drive up standards of care and reduce inappropriate variation in care and health outcomes across the UK.

Improving Outcomes in Lung Cancer Project (ILCOP)

ILCOP has been funded by the Health Foundation and is hosted by the Royal College of Physicians. The project uses NLCA data and a new patient experience questionnaire to drive improvements at local level. ILCOP is in its second year and the 30 trusts who completed reciprocal peer review visits are now undertaking facilitated quality improvement work based on the quality improvement plans they submitted. The plans focus on a wide range of areas, including live data collection, improved MDT working, more streamlined diagnostic and treatment pathways, and increased access to treatments. The overall impact of the project on NLCA headline indicators will be assessed in 2012. Preliminary data measured locally by participating teams have shown encouraging improvements in areas such as the availability of all the key information at the MDT meeting and reductions in treatment delays for small cell cancer.

Trust performance

Handling of low case numbers

It should be noted that trusts submitting very low numbers of cases with high levels of data completeness have been omitted from the tables below to ensure that no details about specific patients can be identified in this report. Because of this network totals may not equal the sum of the composite trusts. For example, in a trust with only two submitted cases of lung cancer, with 100 per cent data completeness and a resection rate of 100 per cent, it would be possible to know the details of treatment of all lung cancer patients seen at that trust. However in most cases, each reported value is composed of multiple variables so it is impossible to surmise information about specific individuals from this report.

Data groupings

The data has been divided into 4 groups for analysis:-

- All cases of lung cancer submitted to the audit (this includes lung cancer and mesothelioma). This is the default grouping on which all analyses have been carried out unless otherwise specified.
- NSCLC – non-small cell lung cancer or, more correctly, this should be considered NOT small cell lung cancer. This group includes all lung cancers including those that are clinically diagnosed, but excludes pathological diagnoses of small cell lung cancer and clinical/ pathological diagnoses of mesothelioma.
- Histologically confirmed non-small cell lung cancer – all cases of non-small cell lung cancer that are confirmed by a histological or cytological specimen.
- Small cell lung cancer – all cases of lung cancer that are confirmed to be of small cell type by a histological or cytological specimen.

Lung Cancer Audit 2011

At the time of publication of this report in December 2011, organisations will still be collecting data on patients first seen in 2011, in preparation for submission to the audit at the end of June 2012. This data will be analysed and published in December 2012.

Organisations should take note of the following:

- It is anticipated that data on co-morbidities will be included in future case-mix adjustment. Strategies to ensure high quality data submission should be adopted. Note that for the purposes of the NLCA, only co-morbidities that influence treatment decisions should be recorded (see data manual for further details).
- It is anticipated that data on lung function (FEV**1** absolute and percentage of predicted) will be included in future case-mix adjustment. Strategies to ensure high quality data submission should be adopted.

Table 1a
Data completeness for key fields England and Wales (2010 all)

Code	Expected number	Actual number	% of expected	MDT Completeness (%)	Performance Status Completeness (%)	Stage Completeness (%)	PS & Stage Completeness (%)	Treatment Recorded (%)	Data Completeness Seen by Nurse Specialist (%)	Data Completeness Nurse Specialist present at Diagnosis (%)	CT Scan Field Completed (%)	Bronchoscopy Field Completed (%)
N01 Total	**989**	**1,081**	**109** ●	**98.1** ●	**76.0** ▲	**86.7** ●	**68.6** ▲	**92.2** ●	**84.4** ▲	**79.3** ▲	**91.6** ●	**43.7** ▲
RTX	184	259	141 ●	98.5 ●	44.8 ▲	75.3 ▲	35.5 ▲	86.9 ●	78.8 ▲	78.0 ▲	82.2 ▲	34.4 ▲
RXL	242	247	102 ●	97.6 ●	96.8 ●	85.0 ●	85.0 ●	99.2 ●	96.0 ●	81.8 ▲	96.0 ●	61.5 ▲
RXN	136	267	196 ●	99.3 ●	83.9 ▲	90.3 ●	77.2 ▲	93.3 ●	87.6 ●	82.4 ▲	95.1 ●	34.5 ▲
RXR	427	308	72 ■	97.1 ●	78.9 ▲	94.5 ●	76.0 ▲	90.3 ●	76.9 ▲	75.6 ▲	92.9 ●	45.1 ▲
N02 Total	**2,184**	**2,217**	**102** ●	**95.5** ●	**84.9** ▲	**79.1** ▲	**74.5** ▲	**80.2** ▲	**75.6** ▲	**69.0** ▲	**92.6** ●	**71.9** ▲
RBT	120	121	101 ●	86.0 ▲	19.0 ▲	20.7 ▲	4.1 ▲	86.0 ●	41.3 ▲	41.3 ▲	70.2 ▲	66.1 ▲
RBV ◆	0 ◆	3 ◆	0 ◆	66.7 ◆	66.7 ◆	66.7 ◆	66.7 ◆	66.7 ◆	66.7 ◆	66.7 ◆	66.7 ◆	33.3 ◆
RJN	108	113	105 ●	98.2 ●	97.3 ●	90.3 ●	90.3 ●	82.3 ▲	94.7 ●	94.7 ●	97.3 ●	57.5 ▲
RM2 ◆	236 ◆	193 ◆	82 ◆	93.3 ◆	94.8 ◆	56.5 ◆	54.9 ◆	76.2 ◆	43.5 ◆	43.5 ◆	91.2 ◆	48.2 ◆
RM3	220	225	102 ●	99.1 ●	95.6 ●	97.8 ●	94.7 ●	82.2 ▲	92.0 ●	88.4 ●	97.8 ●	97.8 ●
RM4	92	105	114 ●	100.0 ●	99.0 ●	93.3 ●	92.4 ●	95.2 ●	96.2 ●	92.4 ●	97.1 ●	94.3 ●
RMC	220	224	102 ●	99.1 ●	98.7 ●	98.7 ●	98.2 ●	90.6 ●	99.1 ●	90.2 ●	98.7 ●	98.2 ●
RMP	150	127	85 ●	83.5 ▲	13.4 ▲	23.6 ▲	11.0 ▲	92.1 ●	93.7 ●	71.7 ▲	81.1 ▲	69.3 ▲
RRF	200	217	109 ●	94.9 ▲	86.6 ●	89.9 ●	82.5 ▲	83.4 ▲	94.5 ●	83.9 ▲	94.0 ●	89.4 ●
RW3	120	144	120 ●	95.1 ●	89.6 ●	68.8 ▲	62.5 ▲	84.7 ▲	85.4 ●	60.4 ▲	95.1 ●	95.1 ●
RW6	573	573	100 ●	96.5 ●	95.5 ●	88.7 ●	86.4 ●	82.4 ▲	50.3 ▲	50.3 ▲	91.4 ●	41.2 ▲
RWJ	145	172	119 ●	97.7 ●	83.7 ▲	84.3 ▲	74.4 ▲	29.7 ▲	97.7 ●	82.0 ▲	97.7 ●	93.6 ●

Table 1a (continued)
Data completeness for key fields England and Wales (2010 all)

Code	Expected number	Actual number	% of expected	MDT Completeness (%)	Performance Status Completeness (%)	Stage Completeness (%)	PS & Stage Completeness (%)	Treatment Recorded (%)	Data Completeness Seen by Nurse Specialist (%)	Data Completeness Nurse Specialist present at Diagnosis (%)	CT Scan Field Completed (%)	Bronchoscopy Field Completed (%)
N03 Total	**1,535**	**1,825**	**119** ●	**99.4** ●	**94.0** ●	**95.6** ●	**90.8** ●	**86.4** ●	**91.6** ●	**72.8** ▲	**97.8** ●	**69.6** ▲
RBL	119	290	244 ●	100.0 ●	99.3 ●	99.0 ●	98.6 ●	81.4 ▲	100.0 ●	84.1 ▲	100.0 ●	100.0 ●
RBN	221	235	106 ●	97.4 ●	92.8 ●	93.2 ●	88.5 ●	97.9 ●	73.2 ▲	73.2 ▲	95.7 ●	29.8 ▲
RBQ	212	264	125 ●	99.6 ●	97.3 ●	93.6 ●	92.0 ●	83.0 ▲	98.9 ●	97.3 ●	98.9 ●	95.1 ●
REM	323	336	104 ●	100.0 ●	94.9 ●	99.4 ●	94.3 ●	88.1 ●	97.6 ●	37.5 ▲	99.7 ●	77.7 ▲
REN ◆	48 ◆	2 ◆	4 ◆	100.0 ◆	50.0 ◆	50.0 ◆	50.0 ◆	100.0 ◆	0.0 ◆	0.0 ◆	100.0 ◆	0.0 ◆
RJR	121	168	139 ●	99.4 ●	94.6 ●	98.8 ●	94.0 ●	91.7 ●	90.5 ●	90.5 ●	89.3 ●	33.3 ▲
RQ6	216	146	68 ■	99.3 ●	97.3 ●	94.5 ●	91.8 ●	90.4 ●	98.6 ●	76.7 ▲	97.9 ●	61.6 ▲
RVY	82	197	240 ●	99.0 ●	93.4 ●	90.4 ●	86.3 ●	97.0 ●	82.2 ▲	82.2 ▲	98.5 ●	39.6 ▲
RWW	193	187	97 ●	100.0 ●	78.6 ▲	93.0 ●	75.4 ▲	62.6 ▲	87.2 ●	55.6 ▲	98.9 ●	93.6 ●
N06 Total	**1,811**	**1,859**	**103** ●	**99.5** ●	**94.7** ●	**87.3** ●	**83.9** ▲	**92.3** ●	**93.9** ●	**80.5** ▲	**99.0** ●	**93.6** ●
RAE	240	202	84 ●	100.0 ●	90.6 ●	59.4 ▲	56.4 ▲	100.0 ●	100.0 ●	85.6 ●	100.0 ●	99.5 ●
RCB	173	186	108 ●	98.4 ●	94.1 ●	81.2 ▲	77.4 ▲	91.9 ●	100.0 ●	84.9 ▲	100.0 ●	100.0 ●
RCD	91	109	120 ●	98.2 ●	97.2 ●	94.5 ●	92.7 ●	90.8 ●	95.4 ●	78.9 ▲	99.1 ●	99.1 ●
RCF	118	111	94 ●	100.0 ●	100.0 ●	99.1 ●	99.1 ●	95.5 ●	100.0 ●	91.0 ●	100.0 ●	100.0 ●
RR8	565	516	91 ●	100.0 ●	100.0 ●	94.6 ●	94.6 ●	95.7 ●	100.0 ●	86.2 ●	100.0 ●	100.0 ●
RWY	244	296	121 ●	100.0 ●	91.9 ●	97.6 ●	90.2 ●	95.3 ●	99.3 ●	88.5 ●	100.0 ●	100.0 ●
RXF	380	439	116 ●	99.1 ●	90.4 ●	82.5 ▲	76.5 ▲	82.5 ▲	75.6 ▲	62.0 ▲	96.1 ●	73.3 ▲
N07 Total	**753**	**832**	**111** ●	**98.7** ●	**88.3** ●	**85.3** ●	**77.2** ▲	**94.4** ●	**70.6** ▲	**39.7** ▲	**98.7** ●	**99.2** ●
RCC	126	128	102 ●	100.0 ●	99.2 ●	94.5 ●	93.8 ●	93.0 ●	93.8 ●	79.7 ▲	100.0 ●	99.2 ●
RJL	226	301	133 ●	96.3 ●	69.8 ▲	79.7 ▲	59.1 ▲	95.7 ●	88.0 ●	70.8 ▲	100.0 ●	99.3 ●
RWA	401	403	101 ●	100.0 ●	98.8 ●	86.6 ●	85.4 ●	93.8 ●	50.1 ▲	3.7 ▲	97.3 ●	99.0 ●
N08 Total	**1,246**	**1,337**	**107** ●	**99.9** ●	**99.0** ●	**90.5** ●	**89.8** ●	**94.6** ●	**82.8** ▲	**76.4** ▲	**98.7** ●	**98.7** ●
RFF	131	164	125 ●	98.8 ●	96.3 ●	77.4 ▲	75.0 ▲	96.3 ●	63.4 ▲	63.4 ▲	95.1 ●	95.7 ●
RFR	144	185	129 ●	100.0 ●	100.0 ●	98.4 ●	98.4 ●	95.7 ●	99.5 ●	92.4 ●	100.0 ●	100.0 ●
RFS	174	199	114 ●	100.0 ●	100.0 ●	97.5 ●	97.5 ●	96.5 ●	92.5 ●	66.3 ▲	99.5 ●	100.0 ●
RHQ	480	444	93 ●	100.0 ●	100.0 ●	89.9 ●	89.9 ●	90.8 ●	71.4 ▲	70.7 ▲	98.0 ●	97.5 ●
RP5	317	345	109 ●	100.0 ●	98.0 ●	89.3 ●	87.8 ●	97.1 ●	92.2 ●	87.0 ●	100.0 ●	100.0 ●
N11 Total	**1,066**	**1,009**	**95** ●	**96.3** ●	**95.8** ●	**93.1** ●	**92.1** ●	**95.3** ●	**93.3** ●	**76.0** ▲	**94.4** ●	**46.1** ▲
RBK	158	146	92 ●	93.8 ▲	93.2 ●	91.8 ●	91.1 ●	98.6 ●	87.0 ●	74.0 ▲	90.4 ●	77.4 ▲
RR1	404	397	98 ●	95.2 ●	94.2 ●	87.2 ●	86.1 ●	96.0 ●	94.2 ●	66.5 ▲	93.5 ●	50.6 ▲
RRK	245	199	81 ●	97.5 ●	97.0 ●	98.5 ●	96.0 ●	91.0 ●	90.5 ●	90.5 ●	98.0 ●	27.1 ▲
RXK	259	265	102 ●	99.2 ●	99.6 ●	99.2 ●	99.2 ●	95.8 ●	97.4 ●	80.4 ▲	96.2 ●	36.6 ▲
N12 Total	**414**	**540**	**130** ●	**99.1** ●	**86.7** ●	**81.7** ▲	**73.1** ▲	**92.0** ●	**93.7** ●	**75.4** ▲	**98.1** ●	**91.9** ●
RJC	5	88	1760 ●	97.7 ●	96.6 ●	77.3 ▲	75.0 ▲	89.8 ●	98.9 ●	92.0 ●	100.0 ●	100.0 ●
RKB	249	257	103 ●	100.0 ●	94.2 ●	89.1 ●	84.0 ▲	93.4 ●	99.6 ●	76.3 ▲	100.0 ●	99.2 ●
RLT	96	130	135 ●	97.7 ●	88.5 ●	85.4 ●	76.2 ▲	88.5 ●	89.2 ●	70.8 ▲	98.5 ●	96.9 ●
RWP01	64	65	102 ●	100.0 ●	40.0 ▲	50.8 ▲	21.5 ▲	96.9 ●	72.3 ▲	58.5 ▲	87.7 ●	41.5 ▲
N20 Total	**532**	**579**	**109** ●	**99.8** ●	**89.1** ●	**81.3** ▲	**75.6** ▲	**96.7** ●	**92.6** ●	**87.0** ●	**97.2** ●	**71.0** ▲
RC9	109	153	140 ●	99.3 ●	96.7 ●	82.4 ▲	82.4 ▲	98.7 ●	96.1 ●	83.0 ▲	98.7 ●	68.6 ▲
RWG	217	200	92 ●	100.0 ●	81.5 ▲	70.0 ▲	59.5 ▲	98.5 ●	98.5 ●	94.5 ●	94.5 ●	43.5 ▲
RWH	206	226	110 ●	100.0 ●	90.7 ●	90.7 ●	85.4 ●	93.8 ●	85.0 ●	83.2 ▲	98.7 ●	96.9 ●

Table 1a (continued)
Data completeness for key fields England and Wales (2010 all)

Code	Expected number	Actual number	% of expected	MDT Completeness (%)	Performance Status Completeness (%)	Stage Completeness (%)	PS & Stage Completeness (%)	Treatment Recorded (%)	Data Completeness Seen by Nurse Specialist (%)	Data Completeness Nurse Specialist present at Diagnosis (%)	CT Scan Field Completed (%)	Bronchoscopy Field Completed (%)
N21 Total	**862**	**658**	**76**	**98.6**	**95.9**	**92.2**	**89.2**	**89.8**	**97.0**	**70.4**	**99.2**	**97.0**
RAS	100	120	120	100.0	100.0	89.2	89.2	81.7	100.0	99.2	100.0	100.0
RC3	75	46	61	95.7	91.3	100.0	91.3	89.1	100.0	84.8	100.0	95.7
RFW	70	102	146	100.0	100.0	100.0	100.0	91.2	100.0	0.0	100.0	100.0
RQM	80	61	76	100.0	88.5	82.0	75.4	95.1	100.0	78.7	100.0	96.7
RT3	148	14	10	100.0	85.7	71.4	71.4	100.0	85.7	50.0	85.7	42.9
RV8	100	82	82	91.5	86.6	93.9	82.9	95.1	95.1	69.5	98.8	96.3
RYJ	289	233	81	100.0	98.7	92.3	91.0	89.7	94.0	82.8	99.1	97.9
N22 Total	**732**	**764**	**104**	**97.5**	**92.3**	**90.7**	**86.1**	**86.9**	**97.1**	**81.5**	**97.9**	**97.1**
RAL	86	88	102	100.0	100.0	100.0	100.0	100.0	100.0	97.7	100.0	98.9
RAP	84	71	85	97.2	93.0	78.9	76.1	84.5	98.6	90.1	97.2	97.2
RKE	98	92	94	100.0	89.1	93.5	85.9	96.7	95.7	72.8	100.0	98.9
RQW	113	185	164	95.7	88.1	83.2	78.9	60.0	94.1	61.1	94.1	93.0
RRV	139	121	87	100.0	92.6	100.0	92.6	100.0	96.7	81.8	100.0	99.2
RVL	212	207	98	95.7	93.7	90.8	86.5	94.2	99.0	93.7	98.6	98.1
N23 Total	**780**	**701**	**90**	**96.7**	**61.1**	**81.5**	**54.5**	**87.7**	**71.3**	**54.1**	**86.7**	**72.8**
RF4	340	298	88	97.0	48.0	73.8	38.9	86.2	52.7	22.5	89.6	77.5
RGC	115	109	95	98.2	97.2	94.5	92.7	83.5	94.5	73.4	99.1	100.0
RNH	115	87	76	93.1	23.0	80.5	21.8	80.5	71.3	67.8	35.6	23.0
RNJ[2]	110	108	98	94.4	55.6	73.1	43.5	96.3	73.1	68.5	95.4	50.0
RQX	100	99	99	100.0	100.0	100.0	100.0	93.9	100.0	100.0	100.0	97.0
N24 Total	**873**	**743**	**85**	**96.8**	**79.9**	**78.2**	**69.4**	**75.2**	**85.9**	**72.7**	**87.1**	**53.2**
RJ1	273	120	44	100.0	70.0	88.3	65.8	100.0	86.7	57.5	98.3	98.3
RJ2	116	113	97	84.1	42.5	53.1	32.7	32.7	53.1	33.6	60.2	54.9
RJZ	114	141	124	100.0	97.9	98.6	97.9	53.9	100.0	100.0	100.0	1.4
RYQ	370	368	100	98.4	87.8	74.7	70.9	88.3	90.2	79.1	86.7	57.6
N25 Total	**785**	**619**	**79**	**90.8**	**62.8**	**66.1**	**52.5**	**77.7**	**45.6**	**31.8**	**92.4**	**48.3**
RAX	159	96	60	92.7	79.2	75.0	67.7	87.5	92.7	71.9	96.9	25.0
RJ6	132	135	102	92.6	90.4	89.6	83.7	87.4	88.9	80.7	94.8	30.4
RJ7	239	194	81	88.1	58.8	68.0	44.3	72.2	37.6	9.8	90.2	73.7
RPY	0	6	0	16.7	83.3	100.0	83.3	83.3	0.0	0.0	0.0	0.0
RVR	245	188	77	93.6	38.3	41.5	29.8	71.3	0.0	0.0	93.6	48.4
N26 Total	**920**	**1,135**	**123**	**99.5**	**91.4**	**88.9**	**82.2**	**93.5**	**99.2**	**74.4**	**98.8**	**92.3**
RA9	156	193	124	99.5	99.0	99.5	99.0	97.4	100.0	94.8	100.0	97.9
RBZ	85	122	144	100.0	81.1	81.1	66.4	90.2	100.0	91.8	92.6	39.3
REF	223	312	140	98.7	97.1	91.0	88.5	91.3	99.0	88.8	100.0	99.4
RH8	200	191	96	99.5	93.2	89.5	84.8	95.3	97.4	12.0	97.4	97.4
RK9	256	315	123	100.0	83.8	82.9	70.2	93.3	99.7	78.7	100.0	99.4
N27 Total	**402**	**477**	**119**	**99.6**	**84.3**	**82.2**	**73.4**	**95.8**	**99.0**	**84.3**	**98.5**	**80.1**
RBD	82	140	171	99.3	57.1	70.7	49.3	96.4	98.6	93.6	98.6	97.9
RD3	150	140	93	100.0	95.0	89.3	85.0	99.3	98.6	73.6	97.9	37.1
RDZ	170	197	116	99.5	95.9	85.3	82.2	92.9	99.5	85.3	99.0	98.0

Table 1a (continued)
Data completeness for key fields England and Wales (2010 all)

Code	Expected number	Actual number	% of expected	MDT Completeness (%)	Performance Status Completeness (%)	Stage Completeness (%)	PS & Stage Completeness (%)	Treatment Recorded (%)	Data Completeness Seen by Nurse Specialist (%)	Data Completeness Nurse Specialist present at Diagnosis (%)	CT Scan Field Completed (%)	Bronchoscopy Field Completed (%)
N28 Total	**843**	**912**	**108** ●	**98.2** ●	**37.0** ▲	**66.7** ▲	**29.3** ▲	**88.6** ●	**54.2** ▲	**54.2** ▲	**86.6** ●	**31.0** ▲
RA3	82	92	112 ●	97.8 ●	57.6 ▲	77.2 ▲	53.3 ▲	81.5 ▲	19.6 ▲	19.6 ▲	84.8 ▲	32.6 ▲
RA4	62	77	124 ●	97.4 ●	75.3 ▲	49.4 ▲	40.3 ▲	87.0 ●	75.3 ▲	75.3 ▲	92.2 ●	37.7 ▲
RA7	180	169	94 ●	98.8 ●	8.3 ▲	34.9 ▲	4.7 ▲	89.9 ●	49.7 ▲	49.7 ▲	61.5 ▲	28.4 ▲
RBA	121	163	135 ●	96.9 ●	29.4 ▲	87.7 ●	26.4 ▲	86.5 ●	76.7 ▲	76.7 ▲	95.7 ●	31.9 ▲
RD1	170	199	117 ●	98.5 ●	77.4 ▲	83.9 ▲	65.3 ▲	93.0 ●	85.9 ●	85.9 ●	97.0 ●	33.2 ▲
RVJ	228	212	93 ●	99.1 ●	4.7 ▲	61.3 ▲	2.8 ▲	88.7 ●	17.9 ▲	17.9 ▲	88.7 ●	27.4 ▲
N29 Total	**437**	**511**	**117** ●	**99.8** ●	**80.6** ▲	**81.6** ▲	**69.5** ▲	**88.3** ●	**94.7** ●	**67.7** ▲	**88.1** ●	**85.7** ●
RLQ	74	98	132 ●	100.0 ●	89.8 ●	86.7 ●	79.6 ▲	86.7 ●	96.9 ●	38.8 ▲	99.0 ●	98.0 ●
RTE	244	285	117 ●	100.0 ●	97.5 ●	87.4 ●	86.0 ●	85.3 ●	96.1 ●	69.5 ▲	95.1 ●	97.9 ●
RWP50	119	128	108 ●	99.2 ●	35.9 ▲	64.8 ▲	25.0 ▲	96.1 ●	89.8 ●	85.9 ●	64.1 ▲	49.2 ▲
N30 Total	**1,031**	**1,040**	**101** ●	**98.8** ●	**89.2** ●	**77.3** ▲	**73.0** ▲	**86.5** ●	**93.7** ●	**73.7** ▲	**95.4** ●	**76.8** ▲
RD7	112	133	119 ●	99.2 ●	60.2 ▲	42.9 ▲	33.8 ▲	55.6 ▲	99.2 ●	0.8 ▲	99.2 ●	97.7 ●
RD8	96	79	82 ●	89.9 ▲	77.2 ▲	67.1 ▲	59.5 ▲	82.3 ▲	77.2 ▲	77.2 ▲	74.7 ▲	40.5 ▲
RHW	206	201	98 ●	100.0 ●	94.5 ●	89.1 ●	85.1 ●	97.5 ●	99.5 ●	90.5 ●	100.0 ●	100.0 ●
RN3	113	152	135 ●	100.0 ●	100.0 ●	93.4 ●	93.4 ●	88.8 ●	100.0 ●	84.9 ▲	100.0 ●	100.0 ●
RTH	303	285	94 ●	100.0 ●	91.2 ●	74.0 ▲	68.4 ▲	89.5 ●	87.0 ●	87.0 ●	98.6 ●	55.1 ▲
RXQ	201	188	94 ●	98.4 ●	97.3 ●	85.1 ●	83.5 ▲	92.0 ●	95.2 ●	76.1 ▲	87.8 ●	67.0 ▲
N31[1] Total	**1,092**	**988**	**91** ●	**99.0** ●	**93.0** ●	**86.9** ●	**82.7** ▲	**93.4** ●	**89.9** ●	**73.5** ▲	**83.3** ▲	**78.2** ▲
RHM	448	181	40 ▲	98.9 ●	96.1 ●	93.4 ●	91.2 ●	99.4 ●	96.7 ●	72.9 ▲	98.9 ●	95.6 ●
RHU	279	262	94 ●	98.9 ●	95.8 ●	83.6 ▲	81.7 ▲	95.4 ●	83.6 ▲	68.7 ▲	41.6 ▲	41.6 ▲
RN1	94	121	129 ●	99.2 ●	87.6 ●	78.5 ▲	67.8 ▲	86.8 ●	80.2 ▲	47.9 ▲	95.9 ●	88.4 ●
RN5	39	84	215 ●	96.4 ●	61.9 ▲	66.7 ▲	46.4 ▲	95.2 ●	95.2 ●	76.2 ▲	98.8 ●	98.8 ●
RNZ	71	113	159 ●	99.1 ●	99.1 ●	94.7 ●	93.8 ●	91.2 ●	94.7 ●	88.5 ●	100.0 ●	98.2 ●
5QT	53	99	187 ●	100.0 ●	99.0 ●	93.9 ●	93.9 ●	93.9 ●	99.0 ●	91.9 ●	100.0 ●	96.0 ●
RYR	108	128	119 ●	100.0 ●	98.4 ●	93.8 ●	92.2 ●	87.5 ●	87.5 ●	78.9 ▲	96.9 ●	74.2 ▲
N32 Total	**540**	**608**	**113** ●	**99.8** ●	**62.2** ▲	**83.2** ▲	**56.1** ▲	**89.0** ●	**87.8** ●	**81.6** ▲	**98.5** ●	**75.2** ▲
RA2	109	93	85 ●	100.0 ●	0.0 ▲	39.8 ▲	0.0 ▲	91.4 ●	100.0 ●	62.4 ▲	100.0 ●	100.0 ●
RDU	116	174	150 ●	100.0 ●	89.7 ●	89.7 ●	81.6 ▲	94.8 ●	85.6 ●	84.5 ▲	97.7 ●	27.0 ▲
RTK	159	189	119 ●	99.5 ●	40.2 ▲	97.4 ●	39.2 ▲	90.5 ●	90.5 ●	89.9 ●	98.4 ●	94.2 ●
RTP	156	152	97 ●	100.0 ●	96.1 ●	84.9 ▲	82.2 ▲	78.9 ▲	79.6 ▲	79.6 ▲	98.7 ●	91.4 ●
N33 Total	**620**	**598**	**97** ●	**99.5** ●	**96.0** ●	**93.5** ●	**91.0** ●	**93.0** ●	**77.6** ▲	**77.4** ▲	**95.3** ●	**40.8** ▲
RPL	140	117	84 ●	99.1 ●	90.6 ●	94.9 ●	87.2 ●	90.6 ●	85.5 ●	84.6 ▲	92.3 ●	41.9 ▲
RXC	229	261	114 ●	100.0 ●	99.2 ●	98.9 ●	98.5 ●	95.8 ●	76.6 ▲	76.6 ▲	95.4 ●	44.8 ▲
RXH	251	219	87 ●	99.1 ●	95.0 ●	86.3 ●	84.0 ▲	90.9 ●	74.4 ▲	74.4 ▲	97.3 ●	35.6 ▲
N34 Total	**903**	**1,011**	**112** ●	**99.6** ●	**60.9** ▲	**88.3** ●	**59.1** ▲	**67.7** ▲	**11.8** ▲	**10.9** ▲	**13.5** ▲	**12.0** ▲
RN7	121	114	94 ●	100.0 ●	100.0 ●	86.0 ●	86.0 ●	100.0 ●	100.0 ●	95.6 ●	100.0 ●	100.0 ●
RPA	205	219	107 ●	100.0 ●	0.0 ▲	89.0 ●	0.0 ▲	0.0 ▲	0.5 ▲	0.5 ▲	0.5 ▲	0.0 ▲
RVV	374	493	132 ●	99.4 ●	99.4 ●	99.6 ●	99.2 ●	78.1 ▲	0.0 ▲	0.0 ▲	0.0 ▲	0.0 ▲
RWF	203	185	91 ●	99.5 ●	6.5 ▲	58.9 ▲	5.9 ▲	100.0 ●	2.2 ▲	0.0 ▲	11.4 ▲	3.8 ▲
N35 Total	**1,105**	**1,085**	**98** ●	**95.9** ●	**76.7** ▲	**69.5** ▲	**63.2** ▲	**86.5** ●	**76.8** ▲	**75.5** ▲	**81.8** ▲	**42.9** ▲
RJD	160	148	93 ●	95.9 ●	93.2 ●	83.1 ▲	81.1 ▲	79.1 ▲	90.5 ●	81.1 ▲	95.3 ●	58.1 ▲
RJE	345	289	84 ●	96.5 ●	95.5 ●	64.7 ▲	62.6 ▲	94.5 ●	86.2 ●	86.2 ●	96.9 ●	54.0 ▲
RL4	189	205	109 ●	98.5 ●	94.1 ●	86.8 ●	83.4 ▲	89.3 ●	81.5 ▲	81.5 ▲	78.5 ▲	37.6 ▲
RNA	167	189	113 ●	87.8 ▲	6.3 ▲	21.2 ▲	3.7 ▲	91.5 ●	24.3 ▲	24.3 ▲	86.8 ●	32.8 ▲
RWP31	36	48	133 ●	100.0 ●	43.8 ▲	60.4 ▲	33.3 ▲	97.9 ●	89.6 ●	89.6 ●	56.3 ▲	47.9 ▲
RXW	208	205	99 ●	98.5 ●	93.2 ●	95.6 ●	92.7 ●	70.2 ▲	94.1 ●	94.1 ●	56.1 ▲	29.8 ▲

Table 1a (continued)
Data completeness for key fields England and Wales (2010 all)

Code	Expected number	Actual number	% of expected	MDT Completeness (%)	Performance Status Completeness (%)	Stage Completeness (%)	PS & Stage Completeness (%)	Treatment Recorded (%)	Data Completeness Seen by Nurse Specialist (%)	Data Completeness Nurse Specialist present at Diagnosis (%)	CT Scan Field Completed (%)	Bronchoscopy Field Completed (%)
N36 Total	**2,134**	**2,656**	**125** ●	**98.9** ●	**95.0** ●	**93.2** ●	**89.8** ●	**94.8** ●	**94.5** ●	**82.8** ▲	**98.2** ●	**89.2** ●
RE9	134	181	135 ●	100.0 ●	93.4 ●	84.0 ▲	80.7 ▲	92.8 ●	97.2 ●	88.4 ●	97.2 ●	95.6 ●
RLN	226	273	121 ●	100.0 ●	99.3 ●	97.8 ●	97.1 ●	97.8 ●	97.1 ●	91.9 ●	98.5 ●	89.7 ●
RNL	170	232	137 ●	98.7 ●	86.6 ●	88.4 ●	78.0 ▲	82.8 ▲	83.2 ▲	55.6 ▲	98.7 ●	95.3 ●
RR7	132	221	167 ●	96.8 ●	90.5 ●	86.0 ●	79.6 ▲	92.8 ●	97.7 ●	83.7 ▲	98.2 ●	96.8 ●
RTD	166	317	191 ●	100.0 ●	100.0 ●	94.3 ●	94.3 ●	97.2 ●	100.0 ●	76.0 ▲	100.0 ●	100.0 ●
RTF	364	343	94 ●	94.8 ▲	86.0 ●	86.9 ●	79.6 ▲	90.1 ●	85.7 ●	72.3 ▲	94.8 ●	91.3 ●
RTR	270	351	130 ●	100.0 ●	98.0 ●	99.1 ●	97.2 ●	100.0 ●	100.0 ●	98.0 ●	100.0 ●	98.6 ●
RVW	300	314	105 ●	100.0 ●	98.4 ●	100.0 ●	98.4 ●	100.0 ●	100.0 ●	91.7 ●	100.0 ●	100.0 ●
RXP	372	424	114 ●	99.5 ●	98.1 ●	94.8 ●	93.2 ●	95.5 ●	90.8 ●	83.0 ▲	96.5 ●	53.1 ▲
N37 Total	**1,368**	**1,442**	**105** ●	**93.1** ▲	**66.9** ▲	**76.4** ▲	**58.0** ▲	**89.4** ●	**65.4** ▲	**60.5** ▲	**82.6** ▲	**50.2** ▲
RC1	57	88	154 ●	100.0 ●	78.4 ▲	90.9 ●	73.9 ▲	90.9 ●	73.9 ▲	73.9 ▲	96.6 ●	52.3 ▲
RCX	112	143	128 ●	95.1 ●	83.2 ▲	81.8 ▲	75.5 ▲	88.8 ●	83.2 ▲	83.2 ▲	83.2 ▲	51.7 ▲
RGM ◆	261 ◆	9 ◆	3 ◆	100.0 ◆	100.0 ◆	100.0 ◆	100.0 ◆	33.3 ◆	100.0 ◆	88.9 ◆	100.0 ◆	100.0 ◆
RGN	108	118	109 ●	100.0 ●	75.4 ▲	73.7 ▲	55.9 ▲	98.3 ●	85.6 ●	84.7 ▲	99.2 ●	52.5 ▲
RGP	131	155	118 ●	82.6 ▲	62.6 ▲	54.8 ▲	46.5 ▲	91.0 ●	72.9 ▲	54.8 ▲	78.7 ▲	67.1 ▲
RGQ	171	175	102 ●	97.1 ●	89.1 ●	85.7 ●	77.7 ▲	95.4 ●	94.9 ●	78.3 ▲	97.1 ●	97.1 ●
RGR	52	140	269 ●	100.0 ●	92.9 ●	97.1 ●	91.4 ●	87.1 ●	75.0 ▲	73.6 ▲	89.3 ●	32.1 ▲
RGT	103	186	181 ●	96.8 ●	90.3 ●	88.2 ●	80.6 ▲	78.5 ▲	31.7 ▲	29.6 ▲	32.3 ▲	24.2 ▲
RM1	338	368	109 ●	89.9 ▲	25.0 ▲	63.9 ▲	19.0 ▲	93.8 ●	45.7 ▲	45.4 ▲	89.9 ●	38.6 ▲
RQQ	35	60	171 ●	71.7 ▲	58.3 ▲	63.3 ▲	55.0 ▲	70.0 ▲	63.3 ▲	56.7 ▲	88.3 ●	45.0 ▲
N38 Total	**678**	**815**	**120** ●	**99.9** ●	**99.5** ●	**97.7** ●	**97.2** ●	**97.1** ●	**98.5** ●	**86.4** ●	**87.9** ●	**85.5** ●
RAJ	192	202	105 ●	100.0 ●	100.0 ●	98.0 ●	98.0 ●	100.0 ●	100.0 ●	97.0 ●	99.5 ●	96.0 ●
RDD	176	200	114 ●	100.0 ●	99.0 ●	99.0 ●	98.0 ●	93.5 ●	99.5 ●	79.5 ▲	100.0 ●	100.0 ●
RDE	176	260	148 ●	100.0 ●	100.0 ●	100.0 ●	100.0 ●	100.0 ●	100.0 ●	79.6 ▲	100.0 ●	100.0 ●
RQ8	134	153	114 ●	99.3 ●	98.7 ●	91.5 ●	90.2 ●	92.8 ●	92.8 ●	92.8 ●	35.9 ▲	28.1 ▲
N39 Total	**1,923**	**2,284**	**119** ●	**98.9** ●	**79.6** ▲	**83.5** ▲	**70.8** ▲	**86.4** ●	**86.4** ●	**57.4** ▲	**96.3** ●	**89.4** ●
RJF	62	132	213 ●	100.0 ●	91.7 ●	97.0 ●	90.2 ●	93.2 ●	95.5 ●	60.6 ▲	99.2 ●	98.5 ●
RK5	170	230	135 ●	98.3 ●	93.9 ●	93.9 ●	88.3 ●	89.1 ●	98.7 ●	91.7 ●	100.0 ●	99.6 ●
RNQ	146	198	136 ●	92.4 ▲	82.8 ▲	76.8 ▲	69.2 ▲	51.5 ▲	87.9 ●	83.8 ▲	92.9 ●	87.4 ●
RNS	142	144	101 ●	98.6 ●	62.5 ▲	71.5 ▲	49.3 ▲	86.1 ●	91.0 ●	77.8 ▲	95.8 ●	62.5 ▲
RTG	257	321	125 ●	99.7 ●	83.5 ▲	94.4 ●	79.4 ▲	92.5 ●	100.0 ●	86.0 ●	100.0 ●	99.1 ●
RWD	349	360	103 ●	99.4 ●	61.9 ▲	65.3 ▲	51.7 ▲	90.6 ●	93.3 ●	73.1 ▲	84.7 ▲	60.0 ▲
RWE	465	516	111 ●	100.0 ●	79.3 ▲	83.5 ▲	67.8 ▲	83.5 ▲	57.4 ▲	39.3 ▲	99.2 ●	97.9 ●
RX1	332	378	114 ●	99.7 ●	85.7 ●	88.9 ●	78.0 ▲	96.3 ●	95.8 ●	0.0 ▲	98.9 ●	99.7 ●
NWW Total	**476**	**489**	**103** ●	**99.8** ●	**95.3** ●	**92.2** ●	**89.2** ●	**83.2** ▲	**99.2** ●	**n/a** ◆	**92.2** ●	**45.2**[w1] ◆
7A1A1	182	210	115 ●	99.5 ●	98.6 ●	94.3 ●	92.9 ●	65.7 ▲	100.0 ●	n/a ◆	89.0 ●	42.4 [w1] ◆
7A1A4	152	157	103 ●	100.0 ●	96.8 ●	97.5 ●	94.3 ●	96.2 ●	100.0 ●	n/a ◆	96.8 ●	46.5 [w1] ◆
7A1AU	142	122	86 ●	100.0 ●	87.7 ●	82.0 ▲	76.2 ▲	96.7 ●	96.7 ●	n/a ◆	91.8 ●	48.4 [w1] ◆

Table 1a (continued)
Data completeness for key fields England and Wales (2010 all)

Code	Expected number	Actual number	% of expected	MDT Completeness (%)	Performance Status Completeness (%)	Stage Completeness (%)	PS & Stage Completeness (%)	Treatment Recorded (%)	Data Completeness Seen by Nurse Specialist (%)	Data Completeness Nurse Specialist present at Diagnosis (%)	CT Scan Field Completed (%)	Bronchoscopy Field Completed (%)
SWCN Total	**1,523**	**1,532**	**101** ●	**96.2** ●	**95.4** ●	**96.3** ●	**93.0** ●	**87.8** ●	**91.6** ●	**n/a** ◆	**91.7** ●	**31.8** [w1] ◆
7A2AG	60	50	83 ●	100.0 ●	100.0 ●	100.0 ●	100.0 ●	54.0 ▲	66.0 ▲	n/a ◆	86.0 ●	36.0 [w1] ◆
7A2AJ	32	49	153 ●	100.0 ●	100.0 ●	95.9 ●	95.9 ●	91.8 ●	100.0 ●	n/a ◆	93.9 ●	40.8 [w1] ◆
7A2AL	79	95	120 ●	100.0 ●	100.0 ●	100.0 ●	100.0 ●	64.2 ▲	90.5 ●	n/a ◆	89.5 ●	42.1 [w1] ◆
7A2BL	65	92	142 ●	96.7 ●	71.7 ▲	89.1 ●	67.4 ▲	91.3 ●	93.5 ●	n/a ◆	93.5 ●	40.2 [w1] ◆
7A3B7	97	101	104 ●	64.4 ▲	72.3 ▲	84.2 ▲	67.3 ▲	79.2 ▲	76.2 ▲	n/a ◆	82.2 ▲	10.9 [w1] ◆
7A3C4	123	82	67 ■	96.3 ●	96.3 ●	93.9 ●	92.7 ●	93.9 ●	89.0 ●	n/a ◆	93.9 ●	31.7 [w1] ◆
7A3C7	117	94	80 ●	98.9 ●	100.0 ●	98.9 ●	98.9 ●	96.8 ●	92.6 ●	n/a ◆	94.7 ●	34.0 [w1] ◆
7A3CJ	80	90	113 ●	96.7 ●	96.7 ●	97.8 ●	94.4 ●	87.8 ●	100.0 ●	n/a ◆	87.8 ●	41.1 [w1] ◆
7A4BV ◆	125 ◆	5 ◆	4 ◆	80.0 ◆	80.0 ◆	100.0 ◆	80.0 ◆	100.0 ◆	80.0 ◆	n/a ◆	40.0 ◆	0.0 [w1] ◆
7A4C1	185	287	155 ●	99.7 ●	98.6 ●	95.5 ●	94.4 ●	93.4 ●	93.7 ●	n/a ◆	87.5 ●	27.5 [w1] ◆
7A5B1	131	131	100 ●	93.9 ▲	99.2 ●	100.0 ●	99.2 ●	95.4 ●	92.4 ●	n/a ◆	90.8 ●	22.1 [w1] ◆
7A5B3	123	115	93 ●	99.1 ●	99.1 ●	97.4 ●	96.5 ●	93.0 ●	100.0 ●	n/a ◆	99.1 ●	26.1 [w1] ◆
7A6AM	110	102	93 ●	100.0 ●	98.0 ●	99.0 ●	97.1 ●	76.5 ▲	100.0 ●	n/a ◆	96.1 ●	46.1 [w1] ◆
7A6AR	196	239	122 ●	99.6 ●	99.6 ●	98.3 ●	97.9 ●	91.2 ●	88.3 ●	n/a ◆	97.5 ●	33.9 [w1] ◆
England and Wales Total	**30,424**	**32,347**	**106** ●	**98.0** ●	**84.7** ▲	**85.6** ●	**76.7** ▲	**88.7** ●	**83.4** ▲	**64.9** ▲	**91.2** ●	**70.3** ▲
Range Network												
Min			76	90.8	37.0	66.1	29.3	67.7	11.8	0.0	13.5	12.0
LQ			99	97.0	77.4	81.4	68.8	86.5	77.0	58.2	88.0	46.7
Median			108	98.9	88.7	86.0	75.1	89.2	90.8	73.6	94.9	74.0
UQ			116	99.6	94.9	91.8	89.2	93.5	94.4	78.8	98.2	89.4
Max			130	99.9	99.5	97.7	97.2	97.1	99.2	87.0	99.2	99.2
Range Trust												
Min			0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
LQ			81	96.8	77.7	77.2	63.3	84.9	77.6	44.0	89.5	37.6
Median			102	99.3	93.0	89.1	82.7	91.4	92.8	76.2	97.1	67.9
UQ			121	100.0	98.1	96.7	93.1	96.0	99.0	86.0	99.4	98.0
Max			1760	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Counts aggregated by place first seen trust.

Indicator	Definition
Expected number	Completeness of data based on Expected Annual Cases in Table 1a of the National Lung Cancer Audit 2010
Actual number	Number of cases with date first seen in year specified
% of expected	Completeness of data based on Expected Annual Cases in Table 1a of the National Lung Cancer Audit 2010
MDT Completeness (%)	Complete when MDT Discussion Indicator is Y or N (denominator = all cases)
Performance Status Completeness (%)	Complete when Performance status is present (excluding Not Recorded (5)) (denominator = all cases)
Stage Completeness (%)	Complete when stage can be derived from the following fields: 1) Final pre-treatment TNM category 2) Pathological TNM category 3) Site Specific Stage Classification (excluding Unknown (X)) 4) Post Treatment Site Specific Stage Classification (excluding Unknown (X)) (denominator = all cases)
PS & Stage Completeness (%)	Complete when Performance Status and Stage are both complete (as defined above) (denominator = all cases)
Treatment Recorded (%)	Complete when date present for Brachytherapy, Anti-cancer drug regimen, Surgery, Teletherapy, Palliative or Active Monitoring (denominator = all cases)
Data Completeness Seen by Nurse Specialist (%)	Complete when Patient Assessed by a Lung Cancer Nurse Specialist is Y or N (denominator = all cases)
Data Completeness Nurse Specialist present at Diagnosis (%)	Complete when Lung Cancer Nurse Specialist Present When Received Diagnosis is Y or N (denominator = all cases)
CT Scan Field Completed (%)	Complete when CT Scan is Y or N (denominator = all cases)
Bronchoscopy Field Completed (%)	Complete when Bronchoscopy is Y or N (denominator = all cases) (except Wales)

Footnotes

1) A number of concerns have been raised regarding the current distribution and case number allocation for provider Trusts within Central South Coast Cancer Network (N31)[1]. Trusts have agreed to review the baseline data and methodology used, and have agreed in principle to adjust the per Trust case allocation to inform future reports.

2) Data for Barts and The London NHS Trust (RJN)[2] is incomplete because of technical issues within the trust, and the problem has been identified and will be rectified in the LUCADA database. Performance is not accurately reflected in this report.

W1) In Wales, this field is only completed if the procedure has been performed; there is no yes/no choice.

Key

For per cent of Expected (Case ascertainment)

- ● Case ascertainment exceeds 75 per cent
- ■ Case ascertainment 50-75 per cent
- ▲ Case ascertainment less than 50 per cent
- ◆ Tertiary Trust standards do not apply

For all other data completeness fields

- ● Data completeness exceeds 85 per cent (95 per cent for MDT)
- ▲ Data completeness less than 85 per cent (95 per cent for MDT)
- ◆ Tertiary Trust standards do not apply

Table 1b
Data completeness for key fields Scotland

Health Board	Expected number	Actual number	% of expected	MDT completeness (%)	Performance status completeness (%)	Stage completeness (%)	Treatment recorded (%)	Data completeness seen by nurse specialist (%)	CT scan field completed (%)	Bronchoscopy field completed (%)
SCAN	**1,305**	**1,145**	**88**	**98.7**	**88.9**	**94.2**	**99.9**	**97.5**	**99.2**	**100.0**
Borders	91	90	98	96.7	88.9	96.7	100.0	100.0	100.0	100.0
D & G	146	109	75	100.0	69.7	84.4	100.0	100.0	100.0	100.0
Fife	325	288	89	95.8	80.2	88.9	99.6	90.6	98.3	100.0
Lothian	743	658	89	100.0	95.9	97.9	100.0	99.7	99.4	100.0
WoSCAN	**2,692**	**2,309**	**86**	**99.5**	**90.7**	**86.7**	**99.9**	**98.1**	**100.0**	**99.9**
Ayrshire & Arran	343	305	89	99.7	92.5	91.5	99.7	100.0	100.0	100.0
Forth Valley	252	196	78	100.0	99.0	91.3	100.0	100.0	100.0	100.0
Lanarkshire	528	450	85	100.0	93.1	76.9	99.8	98.4	100.0	100.0
Clyde	388	344	89	98.3	84.9	87.8	100.0	100.0	100.0	100.0
North Glasgow	705	646	92	100.0	87.2	86.2	100.0	95.5	100.0	100.0
South Glasgow	443	360	81	99.4	95.0	92.8	100.0	100.0	100.0	100.0
Lorn & Islands	33	8	24	75.0	25.0	62.5	100.0	12.5	100.0	62.5
NoSCAN	**1,057**	**973**	**92**	**100.0**	**94.6**	**93.6**	**100.0**	**99.5**	**100.0**	**100.0**
Grampian	402	371	92	100.0	89.5	86.4	100.0	100.0	100.0	100.0
Orkney	5	0	0							
Shetland	6	10	167							
Highland	235	211	90	100.0	97.8	99.6	100.0	97.8	100.0	100.0
Western Isles	14	18	129							
Tayside	395	363	92	100.0	97.8	97.5	100.0	100.0	100.0	100.0
Scotland Total	**5,054**	**4,427**	**88**	**99.4**	**91.1**	**90.2**	**99.9**	**98.3**	**99.8**	**99.9**

Cancer Audit data is collected and collated by NHS Greater Glasgow and Clyde [GG&C] as part of the Service Level Agreement NHS Highland [Argyll & Bute] has in place with NHS GG&C. Cancer Audit data and Case Ascertainment figures relating to patients diagnosed within Argyll and Bute, for the purposes of this report, will be shown separately within WoSCAN's analysis. Future analysis of Argyll and Bute patients will be incorporated into NHS Highland analysis, where appropriate.

Table 1c
Data completeness for key fields Northern Ireland

Code	Actual number	MDT Completeness (%)	Performance Status Completeness (%)	Stage Completeness (%)	PS & Stage Completeness (%)	Treatment Recorded (%)	Data Completeness Seen by Nurse Specialist (%)	Data Completeness Nurse Specialist present at Diagnosis (%)	CT Scan Field Completed (%)	Bronchoscopy Field Completed (%)
ZT001	319	100.0 ●	96.9 ●	88.1 ●	85.9 ●	95.0 ●	100.0 ●	n/a ◆	99.7 ●	99.7 ●
ZT002	162	100.0 ●	80.9 ▲	85.8 ●	69.1 ▲	92.6 ●	100.0 ●	n/a ◆	100.0 ●	100.0 ●
ZT003	158	100.0 ●	13.3 ▲	78.5 ▲	11.4 ▲	98.1 ●	91.1 ●	n/a ◆	100.0 ●	100.0 ●
ZT004	201	98.0 ●	84.6 ▲	78.6 ▲	69.7 ▲	98.5 ●	100.0 ●	n/a ◆	100.0 ●	100.0 ●
ZT005	146	100.0 ●	69.2 ▲	44.5 ▲	30.8 ▲	98.6 ●	96.6 ●	n/a ◆	100.0 ●	15.8 ▲
NI Total	**986**	**99.6 ●**	**74.2 ▲**	**77.8 ▲**	**59.7 ▲**	**98.1 ●**	**98.1 ●**	**n/a ◆**	**99.9 ●**	**87.4 ●**

Table 1d
Data completeness for key fields Guernsey

Code	Expected number	Actual number	% of expected	MDT Completeness (%)	Performance Status Completeness (%)	Stage Completeness (%)	PS & Stage Completeness (%)	Treatment Recorded (%)	Data Completeness Seen by Nurse Specialist (%)	Data Completeness Nurse Specialist present at Diagnosis (%)	CT Scan Field Completed (%)	Bronchoscopy Field Completed (%)
Guernsey Total	**36**	**42**	**116**	**N/A**	**97.6**	**76.2**	**76.2**	**69.0**	**N/A**	**100.0**	**97.6**	**100.0**

Table 2a
Process, specialist nursing, imaging and clinical outcomes England and Wales (2010 all) - Part I

Code	Actual number	% of expected	Discussed at MDT (%)	Histo-logical diagnosis (%)	Patient seen by nurse specialist (%)	Nurse specialist present at diagnosis (%)	% Having active treatment	% of patients receiving CT before bronchos-copy	% receiving surgery all cases	% receiving radio-therapy	TNM version 6 stage recorded (%)	TNM version 7 stage recorded (%)
N01 Total	**1,081**	**109** ●	**89.5** ▲	**77.6** ●	**84.0** ●	**41.4** ▲	**58.2** ▲	**91.8** ●	**12.4**	**31.3**	**37.7**	**62.3**
RTX	259	141 ●	82.2 ▲	67.2 ▲	78.8 ▲	31.3 ▲	55.6 ▲	81.4 ▲	10.0	29.0	39.6	60.4
RXL	247	102 ●	82.6 ▲	77.3 ●	94.3 ●	69.6 ▲	69.2 ●	95.3 ●	15.0	36.0	64.9	35.1
RXN	267	196 ●	96.6 ●	93.6 ●	87.6 ●	5.2 ▲	63.7 ●	93.0 ●	16.9	36.0	36.4	63.6
RXR	308	72 ■	95.1 ●	72.7 ▲	76.9 ▲	58.4 ▲	46.8 ▲	94.9 ●	8.4	25.3	18.6	81.4
N02 Total	**2,217**	**102** ●	**94.5** ▲	**72.1** ▲	**70.6** ▲	**44.3** ▲	**51.9** ▲	**82.9** ▲	**12.4**	**26.8**	**36.7**	**63.3**
RBT	121	101 ●	84.3 ▲	81.8 ●	41.3 ▲	2.5 ▲	66.1 ●	65.0 ▲	19.8	41.3	60.0	40.0
RBV ◆	3 ◆	0 ◆	66.7 ◆	33.3 ◆	66.7 ◆	0.0 ◆	33.3 ◆	100.0 ◆	0.0 ◆	33.3 ◆	0.0 ◆	100.0 ◆
RJN	113	105 ●	98.2 ●	70.8 ▲	94.7 ●	68.1 ▲	54.9 ▲	90.8 ●	10.6	40.7	15.0	85.0
RM2 ◆	193 ◆	82 ◆	92.2 ◆	84.5 ◆	43.5 ◆	1.0 ◆	59.1 ◆	92.7 ◆	18.1 ◆	24.9 ◆	48.6 ◆	51.4 ◆
RM3	225	102 ●	97.8 ●	66.7 ▲	89.3 ●	67.6 ▲	46.7 ▲	94.0 ●	9.8	28.4	94.5	5.5
RM4	105	114 ●	100.0 ●	74.3 ▲	93.3 ●	87.6 ●	56.2 ▲	94.2 ●	25.7	21.0	36.7	63.3
RMC	224	102 ●	95.5 ●	62.9 ▲	90.2 ●	72.8 ▲	53.1 ▲	73.1 ▲	9.4	27.2	8.6	91.4
RMP	127	85 ●	82.7 ▲	74.0 ▲	74.8 ▲	36.2 ▲	57.5 ▲	64.8 ▲	6.3	28.3	44.4	55.6
RRF[3]	217	109 ●	94.5 ▲	72.4 ▲	83.9 ●	53.5 ▲	57.1 ▲	81.9 ▲	10.6	42.9	7.1	92.9
RW3	144	120 ●	94.4 ▲	72.2 ▲	79.2 ▲	36.1 ▲	56.3 ▲	95.0 ●	18.8	26.4	94.8	5.2
RW6	573	100 ●	96.5 ●	69.8 ▲	50.3 ▲	32.5 ▲	49.9 ▲	81.8 ▲	10.8	19.9	24.8	75.2
RWJ	172	119 ●	95.9 ●	76.7 ●	82.6 ●	54.1 ▲	26.7 ▲	92.7 ●	8.1	12.8	31.7	68.3
N03 Total	**1,825**	**119** ●	**97.8** ●	**66.8** ▲	**79.5** ▲	**49.2** ▲	**55.7** ▲	**91.0** ●	**15.8**	**31.5**	**30.3**	**69.7**
RBL	290	244 ●	99.0 ●	73.4 ▲	84.1 ●	64.5 ▲	56.9 ▲	82.2 ▲	16.9	35.5	6.6	93.4
RBN	235	106 ●	96.2 ●	60.0 ▲	73.2 ▲	11.1 ▲	54.9 ▲	80.3 ▲	17.4	24.7	34.1	65.9
RBQ	264	125 ●	99.6 ●	85.2 ●	97.7 ●	95.1 ●	75.4 ●	97.1 ●	22.7	48.5	54.7	45.3
REM	336	104 ●	97.6 ●	69.3 ▲	62.5 ▲	5.7 ▲	58.3 ▲	92.6 ●	18.2	28.3	3.9	96.1
REN ◆	2 ◆	4 ◆	100.0 ◆	0.0 ◆	0.0 ◆	0.0 ◆	50.0 ◆	0.0 ◆	0.0 ◆	50.0 ◆	0.0 ◆	100.0 ◆
RJR	168	139 ●	98.2 ●	57.7 ▲	90.5 ●	64.3 ▲	51.2 ▲	92.7 ●	10.7	32.7	8.4	91.6
RQ6	146	68 ■	93.8 ▲	65.8 ▲	81.5 ●	54.8 ▲	38.4 ▲	98.3 ●	8.2	25.3	59.9	40.1
RVY	197	240 ●	99.0 ●	57.4 ▲	82.2 ●	70.1 ▲	49.2 ▲	97.4 ●	10.2	28.9	44.3	55.7
RWW	187	97 ●	97.3 ●	54.5 ▲	71.1 ▲	47.6 ▲	47.1 ▲	87.2 ▲	15.0	21.9	64.4	35.6
N06 Total	**1,859**	**103** ●	**98.9** ●	**73.0** ▲	**81.5** ●	**67.0** ▲	**56.8** ▲	**92.4** ●	**13.3**	**23.1**	**51.7**	**48.3**
RAE	202	84 ●	99.5 ●	69.3 ▲	86.1 ●	61.9 ▲	60.4 ●	97.4 ●	14.9	21.8	100.0	0.0
RCB	186	108 ●	96.8 ●	67.7 ▲	88.7 ●	84.9 ●	57.0 ▲	93.1 ●	16.7	28.5	100.0	0.0
RCD	109	120 ●	97.2 ●	87.2 ●	82.6 ●	72.5 ▲	56.0 ▲	98.1 ●	14.7	9.2	37.6	62.4
RCF	111	94 ●	98.2 ●	68.5 ▲	91.9 ●	64.0 ▲	60.4 ●	93.3 ●	15.3	33.3	100.0	0.0
RR8	516	91 ●	99.0 ●	73.8 ▲	86.4 ●	76.4 ▲	62.8 ●	91.9 ●	12.8	30.4	0.4	99.6
RWY	296	121 ●	100.0 ●	79.1 ●	88.5 ●	66.2 ▲	60.5 ●	86.9 ▲	12.2	25.0	13.2	86.8
RXF	439	116 ●	99.1 ●	69.5 ▲	63.1 ▲	50.8 ▲	44.6 ▲	92.5 ●	11.6	12.5	100.0	0.0
N07 Total	**832**	**111** ●	**96.9** ●	**72.0** ▲	**63.1** ▲	**34.1** ▲	**56.9** ▲	**73.5** ▲	**16.8**	**18.8**	**72.9**	**27.1**
RCC	128	102 ●	99.2 ●	78.1 ●	88.3 ●	72.7 ▲	53.9 ▲	83.8 ▲	9.4	21.9	100.0	0.0
RJL	301	133 ●	92.4 ▲	71.4 ▲	75.7 ▲	58.5 ▲	48.5 ▲	77.8 ▲	12.0	18.6	24.9	75.1
RWA	403	101 ●	99.5 ●	70.5 ▲	45.7 ▲	3.7 ▲	64.0 ●	67.0 ▲	22.8	17.9	99.3	0.7
N08 Total	**1,337**	**107** ●	**99.6** ●	**70.8** ▲	**79.9** ▲	**67.2** ▲	**53.0** ▲	**86.0** ▲	**12.3**	**15.1**	**54.7**	**45.3**
RFF	164	125 ●	97.6 ●	79.3 ●	63.4 ▲	57.9 ▲	52.4 ▲	80.0 ▲	10.4	6.7	37.6	62.4
RFR	185	129 ●	99.5 ●	65.4 ▲	93.0 ●	81.1 ●	51.9 ▲	95.8 ●	10.8	8.6	64.6	35.4
RFS	199	114 ●	100.0 ●	72.4 ▲	85.9 ●	58.3 ▲	44.7 ▲	78.6 ▲	12.1	9.0	99.0	1.0
RHQ	444	93 ●	100.0 ●	70.3 ▲	70.9 ▲	69.6 ▲	54.3 ▲	90.6 ●	12.4	23.0	0.8	99.2
RP5	345	109 ●	100.0 ●	69.3 ▲	88.7 ●	66.1 ▲	57.1 ▲	83.6 ▲	14.2	15.9	98.7	1.3

Table 2a (continued)
Process, specialist nursing, imaging and clinical outcomes England and Wales (2010 all) - Part I

Code	Actual number	% of expected	Discussed at MDT (%)	Histo-logical diagnosis (%)	Patient seen by nurse specialist (%)	Nurse specialist present at diagnosis (%)	% Having active treatment	% of patients receiving CT before bronchos-copy	% receiving surgery all cases	% receiving radio-therapy	TNM version 6 stage recorded (%)	TNM version 7 stage recorded (%)
N11 Total	**1,009**	**95** ●	**95.2** ●	**78.3** ●	**86.1** ●	**59.0** ▲	**60.2** ●	**86.3** ▲	**15.3**	**25.2**	**21.0**	**79.0**
RBK	146	92 ●	91.8 ▲	83.6 ●	74.7 ▲	64.4 ▲	60.3 ●	82.2 ▲	13.0	34.9	47.4	52.6
RR1	397	98 ●	95.0 ●	73.3 ▲	91.7 ●	52.6 ▲	61.0 ●	74.2 ▲	16.9	22.4	0.3	99.7
RRK	199	81 ●	94.0 ▲	83.9 ●	90.5 ●	60.8 ▲	55.8 ▲	100.0 ●	16.1	26.6	4.6	95.4
RXK	265	102 ●	99.2 ●	78.5 ●	80.8 ●	64.2 ▲	61.9 ●	94.7 ●	13.6	22.6	47.1	52.9
N12 Total	**540**	**130** ●	**97.6** ●	**90.4** ●	**78.1** ▲	**50.9** ▲	**59.8** ▲	**82.3** ▲	**15.0**	**29.3**	**33.7**	**66.3**
RJC	88	1760 ●	94.3 ▲	75.0 ●	93.2 ●	68.2 ▲	52.3 ▲	70.8 ▲	9.1	22.7	36.7	63.3
RKB	257	103 ●	100.0 ●	98.8 ●	79.0 ▲	55.6 ▲	61.5 ●	91.5 ●	13.6	37.0	15.1	84.9
RLT	130	135 ●	93.8 ▲	83.1 ●	75.4 ▲	53.1 ▲	64.6 ●	78.9 ▲	22.3	27.7	68.2	31.8
RWP01	65	102 ●	100.0 ●	92.3 ●	60.0 ▲	4.6 ▲	53.8 ▲	69.2 ▲	13.8	10.8	40.6	59.4
N20 Total	**579**	**109** ●	**99.5** ●	**76.3** ●	**89.6** ●	**66.0** ▲	**53.2** ▲	**85.8** ▲	**14.3**	**27.5**	**48.7**	**51.3**
RC9	153	140 ●	98.7 ●	82.4 ●	86.3 ●	64.1 ▲	60.1 ●	88.5 ▲	19.6	37.3	60.5	39.5
RWG	200	92 ●	100.0 ●	76.5 ●	98.0 ●	60.0 ▲	51.5 ▲	87.3 ▲	11.5	27.5	100.0	0.0
RWH	226	110 ●	99.6 ●	72.1 ▲	84.5 ●	72.6 ▲	50.0 ▲	83.1 ▲	13.3	20.8	7.8	92.2
N21 Total	**658**	**76** ●	**98.6** ●	**82.5** ●	**75.8** ▲	**63.2** ▲	**60.9** ●	**92.3** ●	**12.6**	**36.9**	**33.8**	**66.2**
RAS	120	120 ●	100.0 ●	83.3 ●	99.2 ●	99.2 ●	49.2 ▲	98.5 ●	5.8	39.2	2.2	97.8
RC3	46	61 ■	95.7 ●	63.0 ▲	84.8 ●	60.9 ▲	52.2 ▲	100.0 ●	2.2	45.7	51.2	48.8
RFW	102	146 ●	100.0 ●	75.5 ●	0.0 ▲	0.0 ▲	59.8 ▲	90.3 ●	17.6	43.1	4.6	95.4
RQM	61	76 ●	100.0 ●	86.9 ●	78.7 ▲	37.7 ▲	68.9 ●	87.5 ▲	16.4	34.4	97.9	2.1
RT3 ◆	14 ◆	10 ◆	100.0 ◆	92.9 ◆	78.6 ◆	50.0 ◆	92.9 ◆	20.0 ◆	85.7 ◆	14.3 ◆	70.0 ◆	30.0 ◆
RV8	82	82 ●	91.5 ▲	90.2 ●	95.1 ●	69.5 ▲	67.1 ●	86.1 ▲	20.7	18.3	91.8	8.2
RYJ	233	81 ●	100.0 ●	84.5 ●	87.6 ●	78.1 ▲	63.1 ●	96.1 ●	7.7	39.9	19.9	80.1
N22 Total	**764**	**104** ●	**97.1** ●	**80.0** ●	**85.9** ●	**61.1** ▲	**59.8** ▲	**80.7** ▲	**15.1**	**27.4**	**49.5**	**50.5**
RAL	88	102 ●	100.0 ●	93.2 ●	97.7 ●	94.3 ●	64.8 ●	92.3 ●	18.2	28.4	53.8	46.2
RAP	71	85 ●	97.2 ●	74.6 ▲	91.5 ●	81.7 ●	70.4 ●	91.4 ●	18.3	38.0	50.0	50.0
RKE	92	94 ●	100.0 ●	77.2 ●	90.2 ●	54.3 ▲	63.0 ●	100.0 ●	12.0	22.8	2.3	97.7
RQW	185	164 ●	95.1 ●	80.5 ●	61.6 ▲	24.9 ▲	44.3 ▲	77.5 ▲	8.6	21.6	41.1	58.9
RRV	121	87 ●	98.3 ●	92.6 ●	90.9 ●	57.9 ▲	82.6 ●	93.6 ●	16.5	38.0	100.0	0.0
RVL	207	98 ●	95.7 ●	69.6 ▲	95.7 ●	77.3 ▲	53.1 ▲	66.3 ▲	18.8	24.2	43.1	56.9
N23 Total	**701**	**90** ●	**95.0** ●	**75.0** ●	**68.9** ▲	**42.9** ▲	**57.3** ▲	**83.2** ▲	**12.8**	**18.3**	**57.5**	**42.5**
RF4	298	88 ●	93.3 ▲	77.9 ●	51.7 ▲	20.1 ▲	61.4 ●	85.9 ▲	7.0	13.4	43.3	56.7
RGC	109	95 ●	98.2 ●	92.7 ●	83.5 ●	56.0 ▲	60.6 ●	81.4 ▲	19.3	16.5	75.0	25.0
RNH	87	76 ●	92.0 ▲	64.4 ▲	71.3 ▲	65.5 ▲	32.2 ▲	63.6 ▲	8.0	13.8	47.8	52.2
RNJ[2]	108	98 ●	94.4 ▲	68.5 ▲	71.3 ▲	38.0 ▲	66.7 ●	78.7 ▲	19.4	32.4	64.6	35.4
RQX	99	99 ●	100.0 ●	63.6 ▲	100.0 ●	82.8 ●	53.5 ▲	92.3 ●	20.2	23.2	70.7	29.3
N24 Total	**743**	**85** ●	**96.6** ●	**78.3** ●	**81.7** ●	**69.2** ▲	**53.2** ▲	**74.5** ▲	**10.8**	**26.6**	**81.5**	**18.5**
RJ1	120	44 ▲	100.0 ●	95.0 ●	86.7 ●	57.5 ▲	75.8 ●	90.0 ●	16.7	45.0	70.1	29.9
RJ2	113	97 ●	83.2 ▲	62.8 ▲	53.1 ▲	32.7 ▲	19.5 ▲	61.8 ▲	1.8	4.4	98.3	1.7
RJZ	141	124 ●	100.0 ●	77.3 ●	100.0 ●	100.0 ●	53.2 ▲	100.0 ●	11.3	27.7	100.0	0.0
RYQ	368	100 ●	98.4 ●	78.0 ●	81.8 ●	72.3 ▲	56.0 ▲	72.1 ▲	11.4	26.9	72.2	27.8
N25 Total	**619**	**79** ●	**88.7** ▲	**83.5** ●	**43.9** ▲	**30.0** ▲	**52.2** ▲	**79.7** ▲	**11.3**	**23.3**	**65.9**	**34.1**
RAX	96	60 ■	90.6 ▲	93.8 ●	92.7 ●	66.7 ▲	61.5 ●	66.7 ▲	8.3	26.0	60.6	39.4
RJ6	135	102 ●	92.6 ▲	80.0 ●	82.2 ●	80.7 ●	60.7 ●	95.1 ●	17.8	25.2	36.1	63.9
RJ7	194	81 ●	87.6 ▲	89.7 ●	37.1 ▲	6.7 ▲	59.8 ▲	100.0 ●	19.1	28.9	89.1	10.9
RPY ◆	6 ◆	0 ◆	16.7 ◆	100.0 ◆	0.0 ◆	0.0 ◆	66.7 ◆	0.0 ◆	0.0 ◆	16.7 ◆	50.0 ◆	50.0 ◆
RVR	188	77 ●	88.3 ▲	73.9 ▲	0.0 ▲	0.0 ▲	33.0 ▲	74.6 ▲	0.5	14.9	80.0	20.0

Table 2a (continued)
Process, specialist nursing, imaging and clinical outcomes England and Wales (2010 all) - Part I

Code	Actual number	% of expected	Discussed at MDT (%)	Histo-logical diagnosis (%)	Patient seen by nurse specialist (%)	Nurse specialist present at diagnosis (%)	% Having active treatment	% of patients receiving CT before bronchos-copy	% receiving surgery all cases	% receiving radio-therapy	TNM version 6 stage recorded (%)	TNM version 7 stage recorded (%)
N26 Total	**1,135**	**123** ●	**96.3** ●	**73.1** ▲	**86.7** ●	**61.3** ▲	**66.7** ●	**90.8** ●	**15.9**	**43.3**	**43.4**	**56.6**
RA9	193	124 ●	98.4 ●	73.1 ▲	94.8 ●	87.6 ●	63.2 ●	94.0 ●	13.0	49.7	41.2	58.8
RBZ	122	144 ●	93.4 ▲	68.9 ▲	92.6 ●	69.7 ▲	56.6 ▲	72.9 ▲	16.4	16.4	34.4	65.6
REF	312	140 ●	97.8 ●	70.5 ▲	88.8 ●	69.2 ▲	74.7 ●	95.7 ●	19.2	52.6	80.2	19.8
RH8	191	96 ●	96.3 ●	82.2 ●	84.3 ●	10.5[4] ▲	72.3 ●	85.1 ▲	18.3	45.0	0.6	99.4
RK9	315	123 ●	94.6 ▲	71.7 ▲	79.0 ▲	65.1 ▲	61.3 ●	93.7 ●	12.7	39.4	40.2	59.8
N27 Total	**477**	**119** ●	**99.0** ●	**72.7** ▲	**84.3** ●	**55.1** ▲	**55.6** ▲	**88.0** ▲	**11.3**	**30.2**	**35.3**	**64.7**
RBD	140	171 ●	99.3 ●	74.3 ▲	93.6 ●	49.3 ▲	56.4 ▲	93.6 ●	15.0	32.1	61.5	38.5
RD3	140	93 ●	97.9 ●	77.1 ●	73.6 ▲	19.3 ▲	62.9 ●	72.9 ▲	12.9	41.4	42.5	57.5
RDZ	197	116 ●	99.5 ●	68.5 ▲	85.3 ●	84.8 ●	49.7 ▲	93.2 ●	7.6	20.8	16.2	83.8
N28 Total	**912**	**108** ●	**95.7** ●	**77.6** ●	**54.2** ▲	**13.0** ▲	**63.0** ●	**82.5** ▲	**12.9**	**32.6**	**66.7**	**33.3**
RA3	92	112 ●	95.7 ●	79.3 ●	19.6 ▲	3.3 ▲	59.8 ▲	80.0 ▲	10.9	26.1	38.1	61.9
RA4	77	124 ●	96.1 ●	72.7 ▲	75.3 ▲	62.3 ▲	63.6 ●	96.6 ●	10.4	24.7	63.2	36.8
RA7	169	94 ●	98.8 ●	83.4 ●	49.7 ▲	1.8 ▲	68.6 ●	71.8 ▲	20.1	31.4	67.8	32.2
RBA	163	135 ●	93.9 ▲	63.8 ▲	76.7 ▲	37.4 ▲	58.9 ▲	67.3 ▲	11.0	35.0	67.8	32.2
RD1	199	117 ●	98.5 ●	76.4 ●	85.9 ●	0.0 ▲	67.3 ●	93.9 ●	10.1	42.7	100.0	0.0
RVJ	212	93 ●	92.0 ▲	85.8 ●	17.9 ▲	1.9 ▲	59.0 ▲	84.5 ▲	13.2	27.8	36.9	63.1
N29 Total	**511**	**117** ●	**97.1** ●	**84.3** ●	**84.9** ●	**56.6** ▲	**61.8** ●	**75.0** ▲	**13.3**	**35.6**	**78.1**	**21.9**
RLQ	98	132 ●	99.0 ●	78.6 ●	80.6 ●	25.5 ▲	54.1 ▲	85.1 ▲	9.2	27.6	63.1	36.9
RTE	285	117 ●	97.2 ●	81.4 ●	84.6 ●	54.0 ▲	62.8 ●	82.1 ▲	12.3	38.2	97.8	2.2
RWP50	128	108 ●	95.3 ●	95.3 ●	89.1 ●	85.9 ●	65.6 ●	44.1 ▲	18.8	35.9	38.6	61.4
N30 Total	**1,040**	**101** ●	**97.1** ●	**84.9** ●	**74.3** ▲	**56.2** ▲	**59.2** ▲	**92.0** ●	**13.9**	**24.8**	**63.1**	**36.9**
RD7	133	119 ●	91.7 ▲	76.7 ●	5.3 ▲	0.0 ▲	27.8 ▲	69.2 ▲	13.5	3.8	100.0	0.0
RD8	79	82 ●	89.9 ▲	86.1 ●	77.2 ▲	60.8 ▲	68.4 ●	74.2 ▲	8.9	38.0	58.5	41.5
RHW	201	98 ●	96.5 ●	78.6 ●	90.5 ●	41.8 ▲	65.7 ●	98.6 ●	11.9	40.3	29.4	70.6
RN3	152	135 ●	99.3 ●	83.6 ●	84.9 ●	65.1 ▲	54.6 ▲	96.6 ●	14.5	11.8	7.7	92.3
RTH	285	94 ●	100.0 ●	92.3 ●	87.0 ●	83.5 ●	65.6 ●	95.3 ●	17.2	23.9	99.5	0.5
RXQ	188	94 ●	98.4 ●	86.7 ●	76.6 ▲	60.1 ▲	64.4 ●	96.2 ●	13.3	28.7	100.0	0.0
N31[1] Total	**988**	**91** ●	**97.9** ●	**82.4** ●	**74.6** ▲	**55.0** ▲	**73.5** ●	**85.5** ▲	**17.7**	**37.4**	**18.9**	**81.1**
RHM	181	40 ▲	97.2 ●	87.8 ●	74.0 ▲	57.5 ▲	86.7 ●	93.8 ●	21.0	60.2	4.7	95.3
RHU	262	94 ●	98.5 ●	87.8 ●	69.5 ▲	59.5 ▲	84.0 ●	94.4 ●	21.0	34.4	53.9	46.1
RN1	121	129 ●	99.2 ●	89.3 ●	49.6 ▲	40.5 ▲	66.9 ●	74.6 ▲	10.7	28.9	3.2	96.8
RN5	84	215 ●	92.9 ▲	61.9 ▲	79.8 ▲	51.2 ▲	54.8 ▲	92.9 ●	16.7	23.8	18.9	81.1
RNZ	113	159 ●	99.1 ●	75.2 ●	88.5 ●	54.9 ▲	61.1 ●	86.0 ▲	22.1	33.6	2.0	98.0
5QT	99	187 ●	98.0 ●	82.8 ●	93.9 ●	86.9 ●	65.7 ●	75.9 ▲	13.1	35.4	10.8	89.2
RYR	128	119 ●	98.4 ●	76.6 ●	78.9 ▲	33.6 ▲	68.8 ●	79.4 ▲	13.3	33.6	8.3	91.7
N32 Total	**608**	**113** ●	**96.2** ●	**81.1** ●	**81.7** ●	**49.0** ▲	**54.3** ▲	**77.6** ▲	**16.0**	**25.5**	**66.3**	**33.7**
RA2	93	85 ●	90.3 ▲	76.3 ●	62.4 ▲	12.9 ▲	50.5 ▲	90.0 ●	19.4	21.5	83.8	16.2
RDU	174	150 ●	100.0 ●	81.0 ●	84.5 ●	40.2 ▲	51.1 ▲	87.2 ▲	13.2	25.9	100.0	0.0
RTK	189	119 ●	92.6 ▲	78.8 ●	90.5 ●	70.4 ▲	61.4 ●	46.2 ▲	15.3	31.2	61.4	38.6
RTP	152	97 ●	100.0 ●	86.8 ●	79.6 ▲	54.6 ▲	51.3 ▲	89.5 ▲	17.8	20.4	27.3	72.7
N33 Total	**598**	**97** ●	**99.2** ●	**71.2** ▲	**77.4** ▲	**31.4** ▲	**50.7** ▲	**79.1** ▲	**11.7**	**28.8**	**24.0**	**76.0**
RPL	117	84 ●	99.1 ●	70.9 ▲	84.6 ●	51.3 ▲	46.2 ▲	75.5 ▲	8.5	20.5	13.5	86.5
RXC	261	114 ●	100.0 ●	75.1 ●	76.6 ▲	20.7 ▲	54.4 ▲	76.9 ▲	13.8	33.3	33.9	66.1
RXH	219	87 ●	98.2 ●	66.7 ▲	74.4 ▲	33.8 ▲	48.4 ▲	84.6 ▲	11.0	27.9	16.3	83.7

Table 2a (continued)
Process, specialist nursing, imaging and clinical outcomes England and Wales (2010 all) - Part I

Code	Actual number	% of expected	Discussed at MDT (%)	Histo-logical diagnosis (%)	Patient seen by nurse specialist (%)	Nurse specialist present at diagnosis (%)	% Having active treatment	% of patients receiving CT before bronchos-copy	% receiving surgery all cases	% receiving radio-therapy	TNM version 6 stage recorded (%)	TNM version 7 stage recorded (%)
N34 Total	**1,011**	**112** ●	**98.8** ●	**89.8** ●	**11.8** ▲	**9.2** ▲	**48.0** ▲	**100.0** ●	**15.3**	**26.5**	**99.3**	**0.7**
RN7	114	94 ●	100.0 ●	92.1 ●	100.0 ●	81.6 ●	68.4 ●	100.0 ●	14.0	29.8	93.3	6.7
RPA	219	107 ●	100.0 ●	66.2 ▲	0.5 ▲	0.0 ▲	0.0 ▲	0.0 ▲	0.0	0.0	100.0	0.0
RVV	493	132 ●	98.2 ●	96.1 ●	0.0 ▲	0.0 ▲	51.3 ▲	0.0 ▲	18.1	28.0	100.0	0.0
RWF	185	91 ●	98.4 ●	99.5 ●	2.2 ▲	0.0 ▲	83.2 ●	100.0 ●	27.0	51.9	100.0	0.0
N35 Total	**1,085**	**98** ●	**93.5** ▲	**80.1** ●	**75.5** ▲	**46.4** ▲	**59.8** ▲	**82.0** ▲	**16.1**	**31.2**	**26.5**	**73.5**
RJD	148	93 ●	95.3 ●	87.8 ●	81.1 ●	62.8 ▲	61.5 ●	61.9 ▲	14.2	37.2	21.4	78.6
RJE	289	84 ●	96.2 ●	77.5 ●	86.2 ●	33.2 ▲	62.6 ●	92.9 ●	18.7	36.3	31.7	68.3
RL4	205	109 ●	95.6 ●	72.7 ▲	81.5 ●	58.0 ▲	60.0 ●	85.7 ▲	19.0	24.4	8.4	91.6
RNA	189	113 ●	86.2 ▲	78.3 ●	24.3 ▲	16.9 ▲	55.6 ▲	91.8 ●	11.6	25.4	35.0	65.0
RWP31	48	133 ●	89.6 ▲	91.7 ●	89.6 ●	83.3 ●	77.1 ●	56.5 ▲	22.9	29.2	41.4	58.6
RXW	205	99 ●	94.1 ▲	84.4 ●	94.1 ●	59.5 ▲	54.1 ▲	77.0 ▲	13.2	31.7	37.2	62.8
N36 Total	**2,656**	**125** ●	**97.8** ●	**72.3** ▲	**85.2** ●	**71.5** ▲	**60.2** ●	**82.5** ▲	**12.4**	**29.4**	**31.1**	**68.9**
RE9	181	135 ●	100.0 ●	60.2 ▲	88.4 ●	84.5 ●	52.5 ▲	92.4 ●	8.3	30.4	54.1	45.9
RLN	273	121 ●	99.6 ●	82.4 ●	93.4 ●	83.5 ●	61.9 ●	75.0 ▲	19.0	23.4	59.5	40.5
RNL	232	137 ●	98.7 ●	75.0 ●	66.4 ▲	49.6 ▲	62.1 ●	78.0 ▲	12.5	37.9	4.4	95.6
RR7	221	167 ●	96.4 ●	72.4 ▲	90.0 ●	61.1 ▲	57.0 ▲	86.6 ▲	13.1	22.2	5.8	94.2
RTD	317	191 ●	99.1 ●	74.1 ▲	76.0 ▲	56.2 ▲	63.7 ●	86.5 ▲	12.9	36.0	0.0	100.0
RTF	343	94 ●	91.0 ▲	66.5 ▲	72.6 ▲	62.7 ▲	56.0 ▲	71.3 ▲	7.3	19.8	86.6	13.4
RTR	351	130 ●	99.7 ●	73.2 ▲	98.0 ●	96.9 ●	57.5 ▲	91.1 ●	9.1	27.9	8.0	92.0
RVW	314	105 ●	97.1 ●	73.2 ▲	91.7 ●	64.6 ▲	64.3 ●	85.5 ▲	13.4	37.6	33.1	66.9
RXP	424	114 ●	99.5 ●	71.5 ▲	88.2 ●	78.3 ▲	62.7 ●	84.3 ▲	15.1	30.2	30.3	69.8
N37 Total	**1,442**	**105** ●	**91.7** ▲	**80.0** ●	**61.7** ▲	**42.1** ▲	**63.9** ●	**84.1** ▲	**13.6**	**34.7**	**52.7**	**47.3**
RC1	88	154 ●	98.9 ●	78.4 ●	73.9 ▲	30.7 ▲	58.0 ▲	86.4 ▲	9.1	39.8	83.3	16.7
RCX	143	128 ●	89.5 ▲	88.8 ●	83.2 ●	63.6 ▲	63.6 ●	77.0 ▲	11.9	30.1	35.8	64.2
RGM ◆	9 ◆	3 ◆	100.0 ◆	100.0 ◆	100.0 ◆	88.9 ◆	33.3 ◆	100.0 ◆	22.2 ◆	11.1 ◆	44.4 ◆	55.6 ◆
RGN	118	109 ●	98.3 ●	90.7 ●	85.6 ●	34.7 ▲	67.8 ●	93.0 ●	23.7	24.6	75.3	24.7
RGP	155	118 ●	80.0 ▲	80.0 ●	57.4 ▲	32.9 ▲	78.1 ●	89.3 ▲	13.5	45.8	100.0	0.0
RGQ	175	102 ●	94.9 ▲	78.9 ●	79.4 ▲	52.6 ▲	72.6 ●	69.9 ▲	13.1	50.9	99.3	0.7
RGR	140	269 ●	100.0 ●	78.6 ●	74.3 ▲	62.1 ▲	54.3 ▲	97.2 ●	7.1	20.0	22.1	77.9
RGT	186	181 ●	96.8 ●	83.9 ●	31.2 ▲	28.5 ▲	51.6 ▲	92.3 ●	14.5	16.7	19.0	81.0
RM1	368	109 ●	89.7 ▲	72.0 ▲	45.7 ▲	34.0 ▲	69.3 ●	83.6 ▲	14.7	45.4	40.0	60.0
RQQ	60	171 ●	71.7 ▲	80.0 ●	63.3 ▲	53.3 ▲	36.7 ▲	91.7 ●	10.0	11.7	52.6	47.4
N38 Total	**815**	**120** ●	**99.4** ●	**79.8** ●	**86.6** ●	**72.9** ▲	**62.9** ●	**72.1** ▲	**9.4**	**36.1**	**29.1**	**70.9**
RAJ	202	105 ●	99.0 ●	72.8 ▲	97.5 ●	84.2 ●	55.0 ▲	83.1 ▲	6.4	27.7	5.6	94.4
RDD	200	114 ●	100.0 ●	82.5 ●	80.0 ●	59.0 ▲	56.5 ▲	75.2 ▲	10.0	31.5	10.1	89.9
RDE	260	148 ●	99.2 ●	81.9 ●	79.6 ▲	63.5 ▲	72.3 ●	79.8 ▲	10.0	51.9	27.7	72.3
RQ8	153	114 ●	99.3 ●	81.7 ●	92.8 ●	92.2 ●	66.0 ●	23.8 ▲	11.8	26.1	91.4	8.6
N39 Total	**2,284**	**119** ●	**96.1** ●	**73.3** ▲	**79.2** ▲	**41.4** ▲	**60.5** ●	**88.4** ▲	**17.0**	**28.0**	**21.8**	**78.2**
RJF	132	213 ●	99.2 ●	79.5 ●	64.4 ▲	30.3 ▲	72.0 ●	86.5 ▲	23.5	28.0	7.0	93.0
RK5	230	135 ●	97.4 ●	73.0 ▲	98.3 ●	86.5 ●	50.0 ▲	74.3 ▲	12.2	12.6	8.8	91.2
RNQ	198	136 ●	84.8 ▲	74.2 ▲	85.4 ●	65.2 ▲	44.4 ▲	84.2 ▲	13.1	17.7	36.9	63.1
RNS	144	101 ●	95.1 ●	67.4 ▲	79.9 ▲	40.3 ▲	61.8 ●	88.9 ▲	19.4	29.2	62.0	38.0
RTG	321	125 ●	89.1 ▲	74.5 ▲	86.3 ●	67.6 ▲	64.2 ●	95.5 ●	19.9	29.3	2.3	97.7
RWD	360	103 ●	98.1 ●	61.1 ▲	79.4 ▲	28.9 ▲	60.8 ●	80.4 ▲	12.5	33.9	85.3	14.7
RWE	516	111 ●	99.6 ●	70.5 ▲	57.4 ▲	38.4 ▲	60.9 ●	96.6 ●	16.3	32.4	2.4	97.6
RX1	378	114 ●	99.5 ●	88.1 ●	93.9 ●	0.0 ▲	67.5 ●	95.4 ●	21.4	30.2	15.4	84.6

Table 2a (continued)
Process, specialist nursing, imaging and clinical outcomes England and Wales (2010 all) - Part I

Code	Actual number	% of expected	Discussed at MDT (%)	Histo-logical diagnosis (%)	Patient seen by nurse specialist (%)	Nurse specialist present at diagnosis (%)	% Having active treatment	% of patients receiving CT before bronchos-copy	% receiving surgery all cases	% receiving radio-therapy	TNM version 6 stage recorded (%)	TNM version 7 stage recorded (%)
NWW Total	**489**	**103** ●	**99.6** ●	**71.6** ▲	**90.2** ●	**n/a** ◆	**59.7** ▲	**85.1** ▲	**11.0**	**36.6**	**0.0**	**100.0**
7A1A1	210	115 ●	99.5 ●	67.1 ▲	91.0 ●	n/a ◆	58.6 ▲	91.0 ●	8.6	37.1	0.0	100.0
7A1A4	157	103 ●	100.0 ●	73.9 ▲	91.7 ●	n/a ◆	63.1 ●	90.4 ●	14.0	37.6	0.0	100.0
7A1AU	122	86 ●	99.2 ●	76.2 ●	86.9 ●	n/a ◆	57.4 ▲	69.5 ▲	11.5	34.4	0.0	100.0
SWCN Total	**1,532**	**101** ●	**95.1** ●	**70.1** ▲	**78.9** ▲	**n/a** ◆	**58.7** ▲	**85.4** ▲	**10.1**	**39.6**	**0.0**	**100.0**
7A2AG	50	83 ●	96.0 ●	70.0 ▲	30.0 ▲	n/a ◆	42.0 ▲	77.8 ▲	4.0	22.0	0.0	100.0
7A2AJ	49	153 ●	100.0 ●	75.5 ●	0.0 ▲	n/a ◆	53.1 ▲	90.0 ●	6.1	28.6	0.0	100.0
7A2AL	95	120 ●	100.0 ●	74.7 ▲	72.6 ▲	n/a ◆	50.5 ▲	97.5 ●	10.5	34.7	0.0	100.0
7A2BL	92	142 ●	89.1 ▲	73.9 ▲	87.0 ●	n/a ◆	59.8 ▲	70.3 ▲	12.0	30.4	0.0	100.0
7A3B7	101	104 ●	63.4 ▲	63.4 ▲	67.3 ▲	n/a ◆	61.4 ●	50.0 ▲	12.9	42.6	0.0	100.0
7A3C4	82	67 ■	93.9 ▲	79.3 ●	87.8 ●	n/a ◆	57.3 ▲	84.6 ▲	17.1	20.7	0.0	100.0
7A3C7	94	80 ●	98.9 ●	83.0 ●	92.6 ●	n/a ◆	67.0 ●	87.5 ▲	12.8	42.6	0.0	100.0
7A3CJ	90	113 ●	95.6 ●	81.1 ●	93.3 ●	n/a ◆	68.9 ●	67.6 ▲	8.9	48.9	0.0	100.0
7A4BV ◆	5 ◆	4 ◆	80.0 ◆	80.0 ◆	40.0 ◆	n/a ◆	100.0 ◆	0.0 ◆	40.0 ◆	40.0 ◆	0.0 ◆	100.0 ◆
7A4C1	287	155 ●	99.3 ●	62.0 ▲	81.9 ●	n/a ◆	55.1 ▲	84.8 ▲	9.1	38.3	0.0	100.0
7A5B1	131	100 ●	92.4 ▲	82.4 ●	80.9 ●	n/a ◆	70.2 ●	93.1 ●	10.7	54.2	0.0	100.0
7A5B3	115	93 ●	99.1 ●	71.3 ▲	81.7 ●	n/a ◆	62.6 ●	93.3 ●	14.8	45.2	0.0	100.0
7A6AM	102	93 ●	99.0 ●	70.6 ▲	94.1 ●	n/a ◆	62.7 ●	87.2 ▲	6.9	49.0	0.0	100.0
7A6AR	239	122 ●	99.6 ●	58.2 ▲	83.7 ●	n/a ◆	52.3 ▲	92.6 ●	6.7	38.5	0.0	100.0
England and Wales Total	**32,347**	**106** ●	**96.4** ●	**76.0** ●	**75.4** ▲	**48.0** ▲	**58.4** ▲	**84.8** ▲	**13.7**	**29.3**	**40.5**	**59.5**
Range Network												
Min		76	88.7	66.8	11.8	0.0	48.0	72.1	9.4	15.1	0.0	0.7
LQ		99	95.3	72.4	74.4	41.4	54.6	81.0	12.3	25.8	29.4	38.3
Median		108	97.1	77.6	79.4	50.1	59.0	84.6	13.3	29.1	40.6	59.5
UQ		116	98.8	80.9	84.8	61.3	60.4	88.3	15.3	34.2	61.7	70.6
Max		130	99.6	90.4	90.2	72.9	73.5	100.0	17.7	43.3	99.3	100.0
Range Trust												
Min		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
LQ		81	93.9	70.5	69.9	10.7	52.4	74.4	9.4	21.8	6.0	28.2
Median		102	98.2	76.5	82.1	54.1	59.8	86.1	13.0	28.5	37.1	60.2
UQ		121	99.5	83.6	90.2	67.4	64.8	93.2	17.1	37.2	67.1	91.9
Max		1,760	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Counts aggregated by place first seen trust

Indicator	Definition
Actual number	Number of cases with date first seen in year specified
% of expected	Completeness of data in cohort based on Expected Annual Cases in Table 1a of the National Lung Cancer Audit 2009
Discussed at MDT (%)	Complete when MDT Discussion Indicator = Y (denominator = all cases)
Histological diagnosis (%)	Complete when Histology is present or Basis of diagnosis equals 5, 6 or 7 (denominator = all cases)
Patient seen by nurse Specialist (%)	Complete when Patient Assessed by a Lung Cancer Nurse Specialist = Y (denominator = all cases)
Nurse specialist present at diagnosis (%)	Complete when Lung Cancer Nurse Specialist Present When Received Diagnosis = Y (denominator = all cases)
% Having active treatment	Complete when date present for Brachytherapy, Anti-cancer drug regimen, Surgery or Teletherapy (denominator = all cases)
% of patients receiving CT before bronchoscopy	Complete when CT Scan Date before or equal to Bronchoscopy Date (denominator = cases with Bronchoscopy Date present)
% receiving surgery all cases	Complete when Surgery Procedure Date is present (denominator = all cases)
% receiving radiotherapy	Complete when either Teletherapy Treatment Course Start Date or Brachytherapy Therapy Treatment Course Start Date is present (denominator = all cases)
TNM Version 6 stage recorded (%)	Counted when TNM Classification Version Number = 6 or null (denominator = cases with Final Pre-Treatment or Pathological TNM Stage recorded)
TNM Version 7 stage recorded (%)	Counted when TNM Classification Version Number = 7 (denominator = cases with Final Pre-Treatment or Pathological TNM Stage recorded)

Footnotes

1) A number of concerns have been raised regarding the current distribution and case number allocation for provider Trusts within Central South Coast Cancer Network (N31)[1] Trusts have agreed to review the baseline data and methodology used, and have agreed in principle to adjust the per Trust case allocation to inform future reports.

2) Data for Barts and The London NHS Trust (RNJ)[2] is incomplete because of technical issues within the trust, and the problem has been identified and will be rectified in the LUCADA database. Performance is not accurately reflected in this report.

3) Data for small cell chemotherapy for Wrightington, Wigan and Leigh NHS Trust (RRF)[3] is incomplete. Performance of this indicator is not accurately reflected in this report.

4) Royal Devon and Exeter NHS Trust (RH8) did not submit complete data on lung cancer nurse specialist present at diagnosis. The trust report that this should be 75.4 per cent.

Table 2a
Process, specialist nursing, imaging and clinical outcomes England and Wales (2010 all) - Part II

Code	Actual number	% of expected	Number of NSCLC	% of NSCLC having Surgery	NSCLC Stage IA, IB, IIA or IIB	% of NSCLC Stage IA, IB, IIA or IIB having surgery	PS0-1 NSCLC Stage IA, IB, IIA or IIB	% PS0-1 NSCLC Stage IA, IB, IIA or IIB having FEV1 absolute and % predicted
N01 Total	**1,081**	**109** ●	**905**	**13.0** ▲	**223**	**43.5** ▲	**127**	**37.0** ▲
RTX	259	141 ●	213	9.4 ▲	37	37.8 ▲	16	25.0 ▲
RXL	247	102 ●	208	15.9 ●	58	46.6 ▲	40	65.0 ▲
RXN	267	196 ●	218	18.8 ●	67	53.7 ●	35	45.7 ▲
RXR	308	72 ■	266	9.0 ▲	61	32.8 ▲	36	2.8 ▲
N02 Total	**2,217**	**102** ●	**1,883**	**12.6** ▲	**369**	**42.3** ▲	**233**	**37.8** ▲
RBT	121	101 ●	99	20.2 ●	8	100.0 ●	1	0.0 ▲
RBV ◆	3 ◆	0 ◆	3 ◆	0.0 ◆	0 ◆	0.0 ◆	0 ◆	0.0 ◆
RJN	113	105 ●	93	8.6 ▲	20	30.0 ▲	11	54.5 ▲
RM2 ◆	193 ◆	82 ◆	153 ◆	20.3 ◆	49 ◆	49.0 ◆	41 ◆	0.0 ◆
RM3	225	102 ●	187	11.2 ▲	40	35.0 ▲	23	91.3 ●
RM4	105	114 ●	89	27.0 ●	17	47.1 ▲	9	22.2 ▲
RMC	224	102 ●	188	8.0 ▲	35	31.4 ▲	21	76.2 ▲
RMP	127	85 ●	105	7.6 ▲	3	100.0 ●	0	0.0 ▲
RRF[3]	217	109 ●	179	10.1 ▲	33	42.4 ▲	19	84.2 ▲
RW3	144	120 ●	134	19.4 ●	30	63.3 ●	19	63.2 ▲
RW6	573	100 ●	508	10.8 ▲	109	37.6 ▲	70	0.0 ▲
RWJ	172	119 ●	145	7.6 ▲	25	32.0 ▲	19	78.9 ▲
N03 Total	**1,825**	**119** ●	**1,539**	**15.3** ●	**347**	**51.3** ▲	**190**	**56.3** ▲
RBL	290	244 ●	233	14.6 ●	50	46.0 ▲	34	97.1 ●
RBN	235	106 ●	196	14.8 ●	38	50.0 ▲	16	6.3 ▲
RBQ	264	125 ●	215	23.7 ●	63	68.3 ●	48	66.7 ▲
REM	336	104 ●	284	18.3 ●	84	47.6 ▲	42	23.8 ▲
REN ◆	2 ◆	4 ◆	2 ◆	0.0 ◆	0 ◆	0.0 ◆	0 ◆	0.0 ◆
RJR	168	139 ●	148	11.5 ▲	28	35.7 ▲	13	84.6 ▲
RQ6	146	68 ■	116	6.0 ▲	22	31.8 ▲	13	53.8 ▲
RVY	197	240 ●	176	9.7 ▲	31	51.6 ▲	13	92.3 ●
RWW	187	97 ●	169	16.6 ●	31	64.5 ●	11	9.1 ▲
N06 Total	**1,859**	**103** ●	**1,513**	**13.0** ▲	**356**	**41.0** ▲	**195**	**23.1** ▲
RAE	202	84 ●	175	15.4 ●	38	60.5 ●	26	0.0 ▲
RCB	186	108 ●	146	15.1 ●	34	52.9 ●	24	0.0 ▲
RCD	109	120 ●	84	15.5 ●	17	52.9 ●	12	16.7 ▲
RCF	111	94 ●	91	12.1 ▲	17	52.9 ●	13	76.9 ▲
RR8	516	91 ●	427	12.9 ▲	137	33.6 ▲	62	1.6 ▲
RWY	296	121 ●	233	12.4 ▲	55	38.2 ▲	33	63.6 ▲
RXF	439	116 ●	357	11.2 ▲	58	34.5 ▲	25	44.0 ▲
N07 Total	**832**	**111** ●	**661**	**16.0** ●	**118**	**65.3** ●	**95**	**45.3** ▲
RCC	128	102 ●	101	7.9 ▲	10	40.0 ▲	8	25.0 ▲
RJL	301	133 ●	237	9.7 ▲	28	64.3 ●	18	72.2 ▲
RWA	403	101 ●	323	23.2 ●	80	68.8 ●	69	40.6 ▲
N08 Total	**1,337**	**107** ●	**1,114**	**12.9** ▲	**217**	**53.0** ●	**138**	**91.3** ●
RFF	164	125 ●	138	10.1 ▲	17	29.4 ▲	8	100.0 ●
RFR	185	129 ●	157	12.1 ▲	32	53.1 ●	21	100.0 ●
RFS	199	114 ●	166	12.0 ▲	26	65.4 ●	15	73.3 ▲
RHQ	444	93 ●	365	13.7 ▲	87	50.6 ▲	53	92.5 ●
RP5	345	109 ●	288	14.2 ●	55	58.2 ●	41	90.2 ●

Number of PS0-1 NSCLC Stage IIIB or IV	% PS0-1 Stage IIIB or IV NSCLC having chemotherapy	Number of histologically confirmed NSCLC	% histologically confirmed NSCLC having surgery	Number of pre-treatment NSCLC	% pre-treatment NSCLC histology NOS	Number of patients small cell lung cancer	% small cell receiving chemotherapy	Code
134	**60.4** ●	**672**	**17.6**	**672**	**15.5**	**106**	**75.5** ●	**N01 Total**
17	58.8 ●	137	14.6	137	19.7	20	60.0 ▲	RTX
35	60.0 ●	152	21.7	152	15.1	26	84.6 ●	RXL
35	62.9 ●	201	20.4	201	12.9	29	86.2 ●	RXN
47	59.6 ●	182	13.2	182	15.4	31	67.7 ●	RXR
411	**31.6** ▲	**1,272**	**17.8**	**1,252**	**35.1**	**242**	**59.5** ▲	**N02 Total**
1	0.0 ▲	79	25.3	79	48.1	13	46.2 ▲	RBT
0 ◆	0.0 ◆	1 ◆	0.0 ◆	1 ◆	0.0 ◆	0 ◆	0.0 ◆ ◆	RBV
17	41.2 ▲	60	13.3	60	31.7	13	76.9 ●	RJN
25 ◆	52.0 ◆	123 ◆	25.2 ◆	122 ◆	21.3 ◆	28 ◆	67.9 ◆ ◆	RM2
32	31.3 ▲	112	18.8	108	33.3	33	66.7 ●	RM3
15	60.0 ●	62	35.5	58	29.3	15	80.0 ●	RM4
37	40.5 ▲	106	13.2	105	11.4	26	76.9 ●	RMC
6	100.0 ●	72	11.1	68	22.1	19	57.9 ▲	RMP
71	7.0 ▲	119	14.3	119	16.0	26[3]	23.1[3] ▲	RRF
28	25.0 ▲	95	24.2	90	27.8	7	57.1 ▲	RW3
138	38.4 ▲	336	16.1	336	46.1	43	60.5 ▲	RW6
41	12.2 ▲	107	8.4	106	72.6	19	42.1 ▲	RWJ
291	**58.1** ●	**946**	**22.0**	**886**	**18.4**	**203**	**57.6** ▲	**N03 Total**
47	42.6 ▲	159	20.8	151	25.8	36	61.1 ▲	RBL
31	71.0 ●	104	26.0	101	23.8	27	59.3 ▲	RBN
58	69.0 ●	176	24.4	150	9.3	39	79.5 ●	RBQ
61	54.1 ▲	183	25.7	176	24.4	34	55.9 ▲	REM
0 ◆	0.0 ◆	0 ◆	0.0 ◆	0 ◆	0.0 ◆	0 ◆	0.0 ◆ ◆	REN
26	46.2 ▲	78	21.8	78	11.5	16	43.8 ▲	RJR
16	62.5 ●	66	1.5	61	6.6	24	16.7 ▲	RQ6
29	58.6 ●	94	17.0	94	17.0	15	80.0 ●	RVY
23	65.2 ●	86	27.9	75	18.7	12	50.0 ▲	RWW
306	**55.2** ●	**1,016**	**19.0**	**960**	**17.3**	**246**	**72.8** ●	**N06 Total**
22	54.5 ▲	113	23.9	110	20.0	23	69.6 ●	RAE
31	64.5 ●	89	23.6	83	27.7	21	57.1 ▲	RCB
20	75.0 ●	70	18.6	59	16.9	21	66.7 ●	RCD
31	58.1 ●	56	19.6	55	23.6	14	92.9 ●	RCF
77	64.9 ●	293	18.8	293	14.0	65	81.5 ●	RR8
53	41.5 ▲	172	16.9	170	21.2	43	72.1 ●	RWY
72	44.4 ▲	223	16.6	190	11.1	59	67.8 ●	RXF
182	**50.0** ▲	**437**	**17.2**	**397**	**24.4**	**112**	**65.2** ●	**N07 Total**
41	61.0 ●	73	11.0	73	2.7	18	66.7 ●	RCC
54	53.7 ▲	153	15.0	126	30.2	38	65.8 ●	RJL
87	42.5 ▲	211	20.9	198	28.8	56	64.3 ▲	RWA
287	**62.4** ●	**732**	**19.3**	**667**	**36.1**	**145**	**78.6** ●	**N08 Total**
25	76.0 ●	104	13.5	77	53.2	24	66.7 ●	RFF
46	71.7 ●	93	20.4	93	44.1	23	82.6 ●	RFR
39	46.2 ▲	113	15.9	104	36.5	23	56.5 ▲	RFS
94	70.2 ●	235	21.3	234	25.2	36	91.7 ●	RHQ
83	51.8 ▲	187	21.4	159	39.0	39	84.6 ●	RP5

Table 2a (continued)
Process, specialist nursing, imaging and clinical outcomes England and Wales (2010 all) - Part II

Code	Actual number	% of expected	Number of NSCLC	% of NSCLC having Surgery	NSCLC Stage IA, IB, IIA or IIB	% of NSCLC Stage IA, IB, IIA or IIB having surgery	PS0-1 NSCLC Stage IA, IB, IIA or IIB	% PS0-1 NSCLC Stage IA, IB, IIA or IIB having FEV1 absolute and % predicted
N11 Total	**1,009**	**95** ●	**841**	**15.6** ●	**200**	**52.5** ●	**148**	**57.4** ▲
RBK	146	92 ●	127	15.0 ●	29	37.9 ▲	17	17.6 ▲
RR1	397	98 ●	329	15.8 ●	68	61.8 ●	51	52.9 ▲
RRK	199	81 ●	164	18.9 ●	41	65.9 ●	35	88.6 ●
RXK	265	102 ●	219	13.2 ▲	62	40.3 ▲	45	53.3 ▲
N12 Total	**540**	**130** ●	**442**	**14.5** ●	**80**	**51.3** ▲	**48**	**45.8** ▲
RJC	88	1760 ●	77	7.8 ▲	12	50.0 ▲	7	28.6 ▲
RKB	257	103 ●	215	14.4 ●	38	47.4 ▲	27	63.0 ▲
RLT	130	135 ●	99	20.2 ●	25	48.0 ▲	11	18.2 ▲
RWP01	65	102 ●	51	13.7 ▲	5	100.0 ●	3	33.3 ▲
N20 Total	**579**	**109** ●	**466**	**14.6** ●	**67**	**49.3** ▲	**46**	**8.7** ▲
RC9	153	140 ●	120	17.5 ●	12	50.0 ▲	8	25.0 ▲
RWG	200	92 ●	163	11.7 ▲	18	44.4 ▲	13	15.4 ▲
RWH	226	110 ●	183	15.3 ●	37	51.4 ▲	25	0.0 ▲
N21 Total	**658**	**76** ●	**539**	**13.2** ▲	**117**	**48.7** ▲	**79**	**79.7** ▲
RAS	120	120 ●	90	5.6 ▲	8	37.5 ▲	6	83.3 ▲
RC3	46	61 ■	40	0.0 ▲	6	0.0 ▲	5	100.0 ●
RFW	102	146 ●	80	16.3 ●	21	57.1 ●	13	100.0 ●
RQM	61	76 ●	51	15.7 ●	14	50.0 ▲	13	53.8 ▲
RT3 ◆	14 ◆	10 ◆	13 ◆	84.6 ◆	7 ◆	100.0 ◆	2 ◆	0.0 ◆
RV8	82	82 ●	72	23.6 ●	17	82.4 ●	15	100.0 ●
RYJ	233	81 ●	193	8.8 ▲	44	31.8 ▲	25	72.0 ▲
N22 Total	**764**	**104** ●	**618**	**15.2** ●	**129**	**51.9** ▲	**82**	**68.3** ▲
RAL	88	102 ●	68	17.6 ●	13	76.9 ●	10	100.0 ●
RAP	71	85 ●	54	18.5 ●	9	55.6 ●	7	28.6 ▲
RKE	92	94 ●	76	14.5 ●	12	58.3 ●	7	85.7 ●
RQW	185	164 ●	150	9.3 ▲	34	35.3 ▲	21	52.4 ▲
RRV	121	87 ●	97	19.6 ●	18	72.2 ●	14	64.3 ▲
RVL	207	98 ●	173	16.2 ●	43	46.5 ▲	23	78.3 ▲
N23 Total	**701**	**90** ●	**608**	**13.2** ▲	**99**	**50.5** ▲	**45**	**44.4** ▲
RF4	298	88 ●	245	7.8 ▲	29	48.3 ▲	8	50.0 ▲
RGC	109	95 ●	94	17.0 ●	16	68.8 ●	13	100.0 ●
RNH	87	76 ●	77	9.1 ▲	13	30.8 ▲	1	100.0 ●
RNJ[2]	108	98 ●	101	19.8 ●	21	52.4 ●	11	9.1 ▲
RQX	99	99 ●	91	19.8 ●	20	50.0 ▲	12	8.3 ▲
N24 Total	**743**	**85** ●	**627**	**11.0** ▲	**107**	**42.1** ▲	**61**	**39.3** ▲
RJ1	120	44 ▲	101	16.8 ●	27	55.6 ●	16	25.0 ▲
RJ2	113	97 ●	102	2.0 ▲	15	13.3 ▲	5	0.0 ▲
RJZ	141	124 ●	122	12.3 ▲	19	52.6 ●	13	61.5 ▲
RYQ	368	100 ●	301	11.6 ▲	46	39.1 ▲	27	44.4 ▲
N25 Total	**619**	**79** ●	**510**	**11.6** ▲	**75**	**46.7** ▲	**49**	**77.6** ▲
RAX	96	60 ■	78	10.3 ▲	11	45.5 ▲	8	87.5 ●
RJ6	135	102 ●	112	18.8 ●	27	55.6 ●	19	78.9 ▲
RJ7	194	81 ●	162	18.5 ●	30	50.0 ▲	18	88.9 ●
RPY ◆	6 ◆	0 ◆	5 ◆	0.0 ◆	0 ◆	0.0 ◆	0 ◆	0.0 ◆
RVR	188	77 ●	153	0.0 ▲	7	0.0 ▲	4	0.0 ▲

Number of PS0-1 NSCLC Stage IIIB or IV	% PS0-1 Stage IIIB or IV NSCLC having chemotherapy	Number of histologically confirmed NSCLC	% histologically confirmed NSCLC having surgery	Number of pre-treatment NSCLC	% pre-treatment NSCLC histology NOS	Number of patients small cell lung cancer	% small cell receiving chemotherapy	Code
211	**63.0** ●	**626**	**20.9**	**624**	**24.5**	**115**	**63.5** ▲	**N11 Total**
20	85.0 ●	104	18.3	104	33.7	16	56.3 ▲	RBK
78	62.8 ●	225	23.1	223	25.1	43	65.1 ●	RR1
35	68.6 ●	133	23.3	133	12.8	25	48.0 ▲	RRK
78	55.1 ●	162	17.9	162	27.8	31	77.4 ●	RXK
99	**49.5** ▲	**391**	**16.4**	**369**	**15.7**	**63**	**66.7** ●	**N12 Total**
20	75.0 ●	55	10.9	54	24.1	8	75.0 ●	RJC
50	44.0 ▲	212	14.6	193	14.0	34	61.8 ▲	RKB
27	40.7 ▲	77	26.0	75	22.7	15	66.7 ●	RLT
2	50.0 ▲	47	14.9	47	2.1	6	83.3 ●	RWP01
110	**38.2** ▲	**330**	**20.3**	**301**	**31.2**	**70**	**67.1** ●	**N20 Total**
38	39.5 ▲	93	21.5	91	30.8	17	76.5 ●	RC9
27	48.1 ▲	117	16.2	97	32.0	29	58.6 ▲	RWG
45	31.1 ▲	120	23.3	113	31.0	24	70.8 ●	RWH
134	**44.0** ▲	**428**	**16.6**	**406**	**24.1**	**76**	**60.5** ▲	**N21 Total**
35	8.6 ▲	74	6.8	73	30.1	16	62.5 ▲	RAS
6	33.3 ▲	23	0.0	22	27.3	3	66.7 ●	RC3
13	69.2 ●	55	23.6	53	26.4	15	46.7 ▲	RFW
19	63.2 ●	43	18.6	43	11.6	6	66.7 ●	RQM
0 ◆	0.0 ◆	12 ◆	91.7 ◆	8 ◆	0.0 ◆	0 ◆	0.0 ◆ ◆	RT3
11	81.8 ●	64	26.6	61	36.1	7	71.4 ●	RV8
50	48.0 ▲	157	10.8	146	19.9	29	62.1 ▲	RYJ
148	**54.7** ▲	**467**	**20.1**	**421**	**19.7**	**104**	**68.3** ●	**N22 Total**
9	55.6 ●	62	19.4	53	11.3	14	71.4 ●	RAL
9	33.3 ▲	36	27.8	27	18.5	15	80.0 ●	RAP
21	66.7 ●	56	19.6	55	14.5	13	61.5 ▲	RKE
25	40.0 ▲	114	12.3	110	23.6	25	44.0 ▲	RQW
45	64.4 ●	88	21.6	88	12.5	19	94.7 ●	RRV
39	51.3 ▲	111	25.2	88	30.7	18	66.7 ●	RVL
104	**63.5** ●	**442**	**15.8**	**418**	**13.9**	**46**	**73.9** ●	**N23 Total**
33	84.8 ●	181	9.9	178	16.3	27	74.1 ●	RF4
31	61.3 ●	87	18.4	82	14.6	8	75.0 ●	RGC
9	55.6 ●	48	10.4	48	2.1	6	50.0 ▲	RNH
12	50.0 ▲	69	23.2	55	21.8	3	100.0 ●	RNJ[2]
19	42.1 ▲	57	26.3	55	7.3	2	100.0 ●	RQX
103	**57.3** ●	**475**	**13.9**	**448**	**24.3**	**73**	**72.6** ●	**N24 Total**
15	73.3 ●	95	17.9	92	20.7	11	100.0 ●	RJ1
8	12.5 ▲	63	3.2	52	19.2	6	50.0 ▲	RJ2
31	48.4 ▲	92	15.2	91	8.8	13	76.9 ●	RJZ
48	64.6 ●	224	14.7	212	34.0	43	67.4 ●	RYQ
105	**68.6** ●	**413**	**14.0**	**359**	**14.8**	**56**	**58.9** ▲	**N25 Total**
28	71.4 ●	73	11.0	58	24.1	6	66.7 ●	RAX
24	66.7 ●	86	23.3	82	7.3	15	66.7 ●	RJ6
25	52.0 ▲	142	21.1	134	13.4	20	65.0 ●	RJ7
3 ◆	66.7 ◆	5 ◆	0.0 ◆	5 ◆	20.0 ◆	1 ◆	0.0 ◆ ◆	RPY
25	84.0 ●	107	0.0	80	17.5	14	42.9 ▲	RVR

Table 2a (continued)
Process, specialist nursing, imaging and clinical outcomes England and Wales (2010 all) - Part II

Code	Actual number	% of expected	Number of NSCLC	% of NSCLC having Surgery	NSCLC Stage IA, IB, IIA or IIB	% of NSCLC Stage IA, IB, IIA or IIB having surgery	PS0-1 NSCLC Stage IA, IB, IIA or IIB	% PS0-1 NSCLC Stage IA, IB, IIA or IIB having FEV1 absolute and % predicted
N26 Total	**1,135**	**123** ●	**897**	**12.5** ▲	**192**	**46.4** ▲	**126**	**30.2** ▲
RA9	193	124 ●	159	10.1 ▲	34	38.2 ▲	21	81.0 ▲
RBZ	122	144 ●	95	13.7 ▲	17	58.8 ●	12	33.3 ▲
REF	312	140 ●	239	14.2 ●	53	45.3 ▲	38	2.6 ▲
RH8	191	96 ●	153	16.3 ●	37	59.5 ●	30	0.0 ▲
RK9	315	123 ●	249	9.6 ▲	51	39.2 ▲	25	64.0 ▲
N27 Total	**477**	**119** ●	**397**	**9.6** ▲	**49**	**38.8** ▲	**34**	**47.1** ▲
RBD	140	171 ●	116	11.2 ▲	11	45.5 ▲	5	0.0 ▲
RD3	140	93 ●	117	10.3 ▲	19	31.6 ▲	13	0.0 ▲
RDZ	197	116 ●	164	7.9 ▲	19	42.1 ▲	16	100.0 ●
N28 Total	**912**	**108** ●	**751**	**13.6** ▲	**120**	**57.5** ●	**41**	**12.2** ▲
RA3	92	112 ●	78	11.5 ▲	17	35.3 ▲	10	50.0 ▲
RA4	77	124 ●	55	12.7 ▲	11	45.5 ▲	11	0.0 ▲
RA7	169	94 ●	136	20.6 ●	24	75.0 ●	5	0.0 ▲
RBA	163	135 ●	139	10.8 ▲	16	56.3 ●	6	0.0 ▲
RD1	199	117 ●	162	10.5 ▲	18	55.6 ●	8	0.0 ▲
RVJ	212	93 ●	181	14.4 ●	34	61.8 ●	1	0.0 ▲
N29 Total	**511**	**117** ●	**408**	**13.5** ▲	**70**	**54.3** ●	**48**	**16.7** ▲
RLQ	98	132 ●	75	9.3 ▲	7	71.4 ●	7	57.1 ▲
RTE	285	117 ●	230	12.6 ▲	43	48.8 ▲	32	6.3 ▲
RWP50	128	108 ●	103	18.4 ●	20	60.0 ●	9	22.2 ▲
N30 Total	**1,040**	**101** ●	**884**	**13.8** ▲	**150**	**60.0** ●	**106**	**62.3** ▲
RD7	133	119 ●	131	12.2 ▲	16	43.8 ▲	13	0.0 ▲
RD8	79	82 ●	68	7.4 ▲	6	33.3 ▲	1	0.0 ▲
RHW	201	98 ●	179	12.3 ▲	34	58.8 ●	25	88.0 ●
RN3	152	135 ●	115	13.0 ▲	25	52.0 ●	11	54.5 ▲
RTH	285	94 ●	229	18.3 ●	43	74.4 ●	34	97.1 ●
RXQ	188	94 ●	160	13.8 ▲	26	61.5 ●	22	22.7 ▲
N31[1] Total	**988**	**91** ●	**800**	**15.3** ●	**130**	**56.9** ●	**91**	**41.8** ▲
RHM	181	40 ▲	144	17.4 ●	22	63.6 ●	16	50.0 ▲
RHU	262	94 ●	204	17.6 ●	36	61.1 ●	23	0.0 ▲
RN1	121	129 ●	96	10.4 ▲	12	50.0 ▲	4	0.0 ▲
RN5	84	215 ●	67	11.9 ▲	7	71.4 ●	5	80.0 ▲
RNZ	113	159 ●	100	21.0 ●	18	55.6 ●	15	26.7 ▲
5QT	99	187 ●	81	9.9 ▲	12	33.3 ▲	9	88.9 ●
RYR	128	119 ●	108	13.0 ▲	23	56.5 ●	19	73.7 ▲
N32 Total	**608**	**113** ●	**498**	**16.5** ●	**85**	**52.9** ●	**40**	**47.5** ▲
RA2	93	85 ●	76	21.1 ●	8	87.5 ●	0	0.0 ▲
RDU	174	150 ●	146	13.7 ▲	29	48.3 ▲	16	0.0 ▲
RTK	189	119 ●	153	17.0 ●	26	50.0 ▲	8	62.5 ▲
RTP	152	97 ●	123	16.3 ●	22	50.0 ▲	16	87.5 ●
N33 Total	**598**	**97** ●	**485**	**12.8** ▲	**92**	**44.6** ▲	**64**	**10.9** ▲
RPL	117	84 ●	97	10.3 ▲	16	37.5 ▲	12	58.3 ▲
RXC	261	114 ●	211	13.3 ▲	34	52.9 ●	28	0.0 ▲
RXH	219	87 ●	176	13.6 ▲	42	40.5 ▲	24	0.0 ▲

Number of PS0-1 NSCLC Stage IIIB or IV	% PS0-1 Stage IIIB or IV NSCLC having chemotherapy	Number of histologically confirmed NSCLC	% histologically confirmed NSCLC having surgery	Number of pre-treatment NSCLC	% pre-treatment NSCLC histology NOS	Number of patients small cell lung cancer	% small cell receiving chemotherapy	Code
220	**55.5** ●	**599**	**18.0**	**583**	**19.0**	**134**	**73.9** ●	**N26 Total**
33	63.6 ●	109	13.8	100	3.0	22	77.3 ●	RA9
19	47.4 ▲	58	17.2	55	45.5	18	77.8 ●	RBZ
58	46.6 ▲	148	23.0	148	20.3	40	67.5 ●	REF
45	60.0 ●	120	20.8	116	6.0	18	88.9 ●	RH8
64	57.8 ●	162	14.8	162	28.4	36	69.4 ●	RK9
104	**44.2** ▲	**271**	**13.7**	**256**	**27.7**	**46**	**69.6** ●	**N27 Total**
18	44.4 ▲	81	16.0	73	13.7	12	66.7 ●	RBD
40	40.0 ▲	86	14.0	82	14.6	14	71.4 ●	RD3
46	47.8 ▲	104	11.5	101	48.5	20	70.0 ●	RDZ
75	**48.0** ▲	**550**	**18.5**	**544**	**17.3**	**94**	**78.7** ●	**N28 Total**
13	53.8 ▲	59	15.3	59	16.9	11	63.6 ▲	RA3
5	40.0 ▲	34	20.6	34	29.4	18	94.4 ●	RA4
0	0.0 ▲	109	25.7	108	7.4	18	83.3 ●	RA7
19	47.4 ▲	80	18.8	80	27.5	10	80.0 ●	RBA
36	47.2 ▲	117	14.5	115	18.3	23	73.9 ●	RD1
2	50.0 ▲	151	17.2	148	15.5	14	71.4 ●	RVJ
97	**29.9** ▲	**328**	**16.2**	**324**	**36.4**	**68**	**50.0** ▲	**N29 Total**
17	23.5 ▲	54	13.0	52	21.2	17	52.9 ▲	RLQ
74	31.1 ▲	177	15.8	175	44.0	36	50.0 ▲	RTE
6	33.3 ▲	97	18.6	97	30.9	15	46.7 ▲	RWP50
231	**49.8** ▲	**731**	**16.6**	**595**	**36.3**	**101**	**62.4** ▲	**N30 Total**
20	30.0 ▲	100	15.0	3	100.0	0	0.0 ▲	RD7
7	28.6 ▲	57	8.8	56	8.9	7	71.4 ●	RD8
50	60.0 ●	136	16.2	128	49.2	13	53.8 ▲	RHW
25	64.0 ●	92	16.3	91	40.7	24	70.8 ●	RN3
66	51.5 ▲	208	20.2	180	28.3	37	64.9 ▲	RTH
62	43.5 ▲	136	16.2	136	41.2	20	50.0 ▲	RXQ
265	**57.4** ●	**628**	**18.9**	**598**	**29.9**	**96**	**77.1** ●	**N31[1] Total**
39	69.2 ●	123	20.3	114	8.8	18	83.3 ●	RHM
70	44.3 ▲	172	19.8	170	40.6	32	71.9 ●	RHU
24	79.2 ●	83	12.0	78	59.0	11	90.9 ●	RN1
19	31.6 ▲	35	20.0	28	46.4	8	75.0 ●	RN5
39	53.8 ▲	72	29.2	65	23.1	6	100.0 ●	RNZ
34	52.9 ▲	64	12.5	64	7.8	7	85.7 ●	5QT
40	75.0 ●	79	17.7	79	26.6	14	57.1 ▲	RYR
85	**42.4** ▲	**387**	**19.6**	**378**	**19.6**	**72**	**44.4** ▲	**N32 Total**
0	0.0 ▲	54	20.4	54	20.4	13	30.8 ▲	RA2
40	47.5 ▲	114	17.5	112	25.9	20	50.0 ▲	RDU
21	23.8 ▲	115	22.6	110	4.5	22	50.0 ▲	RTK
24	50.0 ▲	104	18.3	102	28.4	17	41.2 ▲	RTP
110	**43.6** ▲	**318**	**18.6**	**313**	**17.6**	**65**	**55.4** ▲	**N33 Total**
27	40.7 ▲	64	14.1	60	43.3	12	58.3 ▲	RPL
59	35.6 ▲	147	17.7	146	15.1	27	70.4 ●	RXC
23	65.2 ●	106	22.6	106	6.6	26	38.5 ▲	RXH

Table 2a (continued)
Process, specialist nursing, imaging and clinical outcomes England and Wales (2010 all) - Part II

Code	Actual number	% of expected	Number of NSCLC	% of NSCLC having Surgery	NSCLC Stage IA, IB, IIA or IIB	% of NSCLC Stage IA, IB, IIA or IIB having surgery	PS0-1 NSCLC Stage IA, IB, IIA or IIB	% PS0-1 NSCLC Stage IA, IB, IIA or IIB having FEV1 absolute and % predicted
N34 Total	**1,011**	**112** ●	**838**	**14.1** ●	**166**	**40.4** ▲	**83**	**20.5** ▲
RN7	114	94 ●	94	13.8 ▲	26	46.2 ▲	18	94.4 ●
RPA	219	107 ●	168	0.0 ▲	21	0.0 ▲	0	0.0 ▲
RVV	493	132 ●	428	15.9 ●	107	43.9 ▲	65	0.0 ▲
RWF	185	91 ●	148	25.0 ●	12	66.7 ●	0	0.0 ▲
N35 Total	**1,085**	**98** ●	**907**	**16.8** ●	**141**	**63.8** ●	**92**	**39.1** ▲
RJD	148	93 ●	113	16.8 ●	18	83.3 ●	14	92.9 ●
RJE	289	84 ●	235	18.3 ●	33	72.7 ●	28	3.6 ▲
RL4	205	109 ●	183	19.7 ●	38	68.4 ●	30	70.0 ▲
RNA	189	113 ●	155	12.9 ▲	13	76.9 ●	3	33.3 ▲
RWP31	48	133 ●	41	24.4 ●	5	80.0 ●	0	0.0 ▲
RXW	205	99 ●	179	12.8 ▲	34	32.4 ▲	17	0.0 ▲
N36 Total	**2,656**	**125** ●	**2,183**	**12.7** ▲	**477**	**44.4** ▲	**285**	**64.9** ▲
RE9	181	135 ●	152	9.9 ▲	32	37.5 ▲	21	76.2 ▲
RLN	273	121 ●	223	20.2 ●	62	56.5 ●	38	81.6 ▲
RNL	232	137 ●	184	10.9 ▲	36	47.2 ▲	25	84.0 ▲
RR7	221	167 ●	184	14.7 ●	43	39.5 ▲	18	55.6 ▲
RTD	317	191 ●	254	13.4 ▲	56	46.4 ▲	35	65.7 ▲
RTF	343	94 ●	286	7.0 ▲	29	41.4 ▲	14	100.0 ●
RTR	351	130 ●	280	9.6 ▲	66	31.8 ▲	33	63.6 ▲
RVW	314	105 ●	266	14.3 ●	73	43.8 ▲	46	43.5 ▲
RXP	424	114 ●	354	14.7 ●	80	50.0 ▲	55	52.7 ▲
N37 Total	**1,442**	**105** ●	**1,172**	**13.4** ▲	**184**	**50.5** ▲	**97**	**36.1** ▲
RC1	88	154 ●	67	7.5 ▲	14	28.6 ▲	4	75.0 ▲
RCX	143	128 ●	111	13.5 ▲	18	61.1 ●	13	23.1 ▲
RGM ◆	9 ◆	3 ◆	9 ◆	22.2 ◆	4 ◆	50.0 ◆	3 ◆	66.7 ◆
RGN	118	109 ●	95	20.0 ●	21	61.9 ●	14	64.3 ▲
RGP	155	118 ●	123	12.2 ▲	14	42.9 ▲	12	8.3 ▲
RGQ	175	102 ●	132	13.6 ▲	16	81.3 ●	14	92.9 ●
RGR	140	269 ●	118	6.8 ▲	13	46.2 ▲	9	22.2 ▲
RGT	186	181 ●	148	14.2 ●	28	50.0 ▲	17	11.8 ▲
RM1	368	109 ●	316	15.2 ●	50	40.0 ▲	6	0.0 ▲
RQQ	60	171 ●	53	11.3 ▲	6	66.7 ●	5	0.0 ▲
N38 Total	**815**	**120** ●	**645**	**11.0** ▲	**106**	**53.8** ●	**70**	**81.4** ▲
RAJ	202	105 ●	160	7.5 ▲	20	40.0 ▲	11	100.0 ●
RDD	200	114 ●	158	10.8 ▲	28	53.6 ●	23	91.3 ●
RDE	260	148 ●	206	11.7 ▲	37	54.1 ●	25	96.0 ●
RQ8	153	114 ●	121	14.9 ●	21	66.7 ●	11	9.1 ▲
N39 Total	**2,284**	**119** ●	**1,941**	**16.8** ●	**393**	**57.0** ●	**251**	**84.1** ▲
RJF	132	213 ●	106	24.5 ●	18	66.7 ●	14	71.4 ▲
RK5	230	135 ●	181	12.2 ▲	33	51.5 ▲	24	95.8 ●
RNQ	198	136 ●	166	13.9 ▲	30	50.0 ▲	17	41.2 ▲
RNS	144	101 ●	109	18.3 ●	26	46.2 ▲	12	50.0 ▲
RTG	321	125 ●	273	20.1 ●	82	54.9 ●	59	98.3 ●
RWD	360	103 ●	321	11.8 ▲	45	57.8 ●	24	87.5 ●
RWE	516	111 ●	424	15.6 ●	71	57.7 ●	39	82.1 ▲
RX1	378	114 ●	356	21.3 ●	86	64.0 ●	61	86.9 ●

Number of PS0-1 NSCLC Stage IIIB or IV	% PS0-1 Stage IIIB or IV NSCLC having chemotherapy	Number of histologically confirmed NSCLC	% histologically confirmed NSCLC having surgery	Number of pre-treatment NSCLC	% pre-treatment NSCLC histology NOS	Number of patients small cell lung cancer	% small cell receiving chemotherapy	Code
150	**40.0** ▲	**739**	**16.0**	**555**	**19.1**	**94**	**41.5** ▲	**N34 Total**
23	52.2 ▲	85	15.3	85	20.0	12	58.3 ▲	RN7
0	0.0 ▲	98	0.0	70	20.0	29	0.0 ▲	RPA
125	38.4 ▲	409	16.6	259	19.7	33	48.5 ▲	RVV
2	0.0 ▲	147	25.2	141	17.0	20	80.0 ●	RWF
171	**52.0** ▲	**694**	**21.3**	**683**	**22.0**	**121**	**57.9** ▲	**N35 Total**
16	68.8 ●	95	20.0	93	35.5	30	40.0 ▲	RJD
54	51.9 ▲	170	25.3	167	20.4	40	62.5 ▲	RJE
54	61.1 ●	128	26.6	123	23.6	12	83.3 ●	RL4
1	0.0 ▲	115	16.5	114	14.0	22	54.5 ▲	RNA
4	75.0 ●	38	26.3	38	18.4	5	100.0 ●	RWP31
41	34.1 ▲	147	15.0	147	21.1	12	50.0 ▲	RXW
509	**62.3** ●	**1,476**	**18.8**	**1,419**	**29.0**	**307**	**63.2** ▲	**N36 Total**
32	34.4 ▲	80	18.8	69	36.2	12	50.0 ▲	RE9
32	68.8 ●	175	25.7	168	43.5	33	69.7 ●	RLN
44	59.1 ●	128	15.6	126	29.4	34	52.9 ▲	RNL
28	53.6 ▲	123	22.0	107	42.1	26	69.2 ●	RR7
54	66.7 ●	173	19.7	173	17.3	43	74.4 ●	RTD
67	68.7 ●	174	11.5	162	27.8	38	57.9 ▲	RTF
69	78.3 ●	194	13.9	194	4.6	47	59.6 ▲	RTR
64	60.9 ●	191	19.9	191	23.0	29	65.5 ●	RVW
119	57.1 ●	238	21.4	229	45.0	45	62.2 ▲	RXP
223	**59.2** ●	**887**	**17.6**	**829**	**21.5**	**150**	**64.0** ▲	**N37 Total**
10	70.0 ●	48	10.4	48	10.4	13	69.2 ●	RC1
33	75.8 ●	95	15.8	95	29.5	23	82.6 ●	RCX
3 ◆	0.0 ◆	9 ◆	22.2 ◆	9 ◆	11.1 ◆	0 ◆	0.0 ◆	◆ RGM
18	55.6 ●	84	22.6	79	36.7	9	88.9 ●	RGN
31	58.1 ●	93	16.1	87	9.2	12	58.3 ▲	RGP
30	53.3 ▲	97	17.5	87	21.8	27	66.7 ●	RGQ
29	65.5 ●	88	9.1	87	34.5	14	57.1 ▲	RGR
31	41.9 ▲	118	17.8	93	9.7	24	41.7 ▲	RGT
28	67.9 ●	214	22.4	213	19.7	24	58.3 ▲	RM1
10	50.0 ▲	41	14.6	31	22.6	4	75.0 ●	RQQ
179	**64.2** ●	**484**	**14.5**	**478**	**33.3**	**106**	**61.3** ▲	**N38 Total**
45	60.0 ●	108	11.1	103	35.0	28	50.0 ▲	RAJ
45	51.1 ▲	123	13.8	122	27.9	27	44.4 ▲	RDD
73	72.6 ●	160	15.0	160	43.8	29	79.3 ●	RDE
16	75.0 ●	93	18.3	93	20.4	22	72.7 ●	RQ8
446	**51.6** ▲	**1,354**	**22.7**	**1,086**	**21.5**	**216**	**69.0** ●	**N39 Total**
35	71.4 ●	82	31.7	64	12.5	19	78.9 ●	RJF
49	42.9 ▲	119	18.5	114	18.4	38	78.9 ●	RK5
31	41.9 ▲	116	19.8	100	41.0	22	50.0 ▲	RNQ
8	50.0 ▲	66	25.8	60	11.7	21	47.6 ▲	RNS
77	61.0 ●	192	27.1	168	42.9	29	69.0 ●	RTG
64	50.0 ▲	189	12.7	141	18.4	19	63.2 ▲	RWD
94	50.0 ▲	278	23.7	228	25.4	58	75.9 ●	RWE
88	46.6 ▲	311	24.4	211	0.5	10	70.0 ●	RX1

Table 2a (continued)
Process, specialist nursing, imaging and clinical outcomes England and Wales (2010 all) - Part II

Code	Actual number	% of expected	Number of NSCLC	% of NSCLC having Surgery	NSCLC Stage IA, IB, IIA or IIB	% of NSCLC Stage IA, IB, IIA or IIB having surgery	PS0-1 NSCLC Stage IA, IB, IIA or IIB	% PS0-1 NSCLC Stage IA, IB, IIA or IIB having FEV1 absolute and % predicted
NWW Total	**489**	**103** ●	**387**	**11.6** ▲	**77**	**42.9** ▲	**51**	**29.4** ▲
7A1A1	210	115 ●	162	7.4 ▲	29	24.1 ▲	18	44.4 ▲
7A1A4	157	103 ●	132	15.2 ●	36	47.2 ▲	22	13.6 ▲
7A1AU	122	86 ●	93	14.0 ●	12	75.0 ●	11	36.4 ▲
SWCN Total	**1,532**	**101** ●	**1,272**	**10.6** ▲	**289**	**37.7** ▲	**189**	**37.0** ▲
7A2AG	50	83 ●	45	4.4 ▲	7	28.6 ▲	4	75.0 ▲
7A2AJ	49	153 ●	41	7.3 ▲	11	27.3 ▲	6	83.3 ▲
7A2AL	95	120 ●	80	10.0 ▲	14	42.9 ▲	10	90.0 ●
7A2BL	92	142 ●	74	12.2 ▲	14	42.9 ▲	11	0.0 ▲
7A3B7	101	104 ●	87	12.6 ▲	16	62.5 ●	11	0.0 ▲
7A3C4	82	67 ■	69	17.4 ●	13	69.2 ●	12	66.7 ▲
7A3C7	94	80 ●	71	15.5 ●	23	47.8 ▲	14	85.7 ●
7A3CJ	90	113 ●	68	10.3 ▲	11	54.5 ●	10	0.0 ▲
7A4BV ◆	5 ◆	4 ◆	4 ◆	25.0 ◆	1 ◆	100.0 ◆	1 ◆	100.0 ◆
7A4C1	287	155 ●	233	8.2 ▲	70	22.9 ▲	47	19.1 ▲
7A5B1	131	100 ●	116	12.1 ▲	30	40.0 ▲	22	77.3 ▲
7A5B3	115	93 ●	102	14.7 ●	24	41.7 ▲	13	0.0 ▲
7A6AM	102	93 ●	81	8.6 ▲	13	38.5 ▲	8	75.0 ▲
7A6AR	239	122 ●	201	8.0 ▲	42	28.6 ▲	20	0.0 ▲
England and Wales Total	**32,347**	**106** ●	**26,731**	**13.7** ▲	**5,225**	**48.8** ▲	**3,204**	**49.7** ▲
Range Network								
Min		0		0.0		0.0		0.0
LQ		96		10.5		39.1		21.3
Median		108		12.6		50.0		57.1
UQ		124		15.7		57.3		83.7
Max		171		24.4		100.0		100.0
Range Trust								
Min		0		0.0		0.0		0.0
LQ		94		11.0		41.9		8.6
Median		106		13.6		50.0		45.5
UQ		121		16.4		58.8		77.1
Max		1,760		84.6		100.0		100.0

	Number of PS0-1 NSCLC Stage IIIB or IV	% PS0-1 Stage IIIB or IV NSCLC having chemotherapy	Number of histologically confirmed NSCLC	% histologically confirmed NSCLC having surgery	Number of pre-treatment NSCLC	% pre-treatment NSCLC histology NOS	Number of patients small cell lung cancer	% small cell receiving chemotherapy	Code
	106	**57.5** ●	**250**	**17.6**	**251**	**17.9**	**78**	**64.1** ▲	**NWW Total**
	50	56.0 ●	94	12.8	95	32.6	36	61.1 ▲	7A1A1
	28	64.3 ●	92	21.7	92	5.4	20	70.0 ●	7A1A4
	28	53.6 ▲	64	18.8	64	14.1	22	63.6 ▲	7A1AU
	336	**49.4** ▲	**820**	**16.2**	**813**	**29.3**	**180**	**66.7** ●	**SWCN Total**
	9	44.4 ▲	30	6.7	30	6.7	4	50.0 ▲	7A2AG
	8	87.5 ●	29	10.3	29	3.4	6	83.3 ●	7A2AJ
	20	25.0 ▲	58	13.8	58	12.1	10	70.0 ●	7A2AL
	21	61.9 ●	50	18.0	51	7.8	15	73.3 ●	7A2BL
	12	25.0 ▲	51	19.6	47	53.2	9	44.4 ▲	7A3B7
	23	73.9 ●	53	22.6	53	18.9	8	50.0 ▲	7A3C4
	23	43.5 ▲	55	20.0	55	32.7	19	89.5 ●	7A3C7
	27	77.8 ●	51	13.7	50	32.0	19	63.2 ▲	7A3CJ
	1 ◆	100.0 ◆	3 ◆	33.3 ◆	3 ◆	33.3 ◆	0 ◆	0.0 ◆	◆ 7A4BV
	61	36.1 ▲	125	15.2	126	30.2	30	73.3 ●	7A4C1
	43	32.6 ▲	93	15.1	93	75.3	14	64.3 ▲	7A5B1
	22	54.5 ▲	70	21.4	69	20.3	8	62.5 ▲	7A5B3
	18	61.1 ●	51	13.7	51	27.5	16	56.3 ▲	7A6AM
	48	54.2 ▲	101	14.9	98	18.4	22	59.1 ▲	7A6AR
	5,932	**52.8** ▲	**19,163**	**18.3**	**17,885**	**24.4**	**3,585**	**65.1** ●	**England and Wales Total**
									Range Network
		0.0		0.0		2.1		0.0	Min
		48.2		13.8		13.1		54.6	LQ
		51.5		16.4		20.0		66.7	Median
		64.0		20.3		28.9		77.1	UQ
		85.0		27.9		59.0		100.0	Max
									Range Trust
		0.0		0.0		0.0		0.0	Min
		41.9		15.0		15.1		57.1	LQ
		53.5		18.6		22.1		66.7	Median
		63.1		21.7		30.7		74.2	UQ
		100.0		91.7		100.0		100.0	Max

Indicator	Definition
Actual number	Number of cases with date first seen in year specified
% of expected	Completeness of data in cohort based on Expected Annual Cases in Table 1a of the National Lung Cancer Audit 2009
Number of NSCLC	Number of NSCLC cases
% of NSCLC having Surgery	Complete when Surgery Procedure Date is present (denominator = NSCLC cases)
NSCLC Stage IA, IB, IIA or IIB	Number of NSCLC cases with TNM Stage IA, IB, IIA or IIB
% of NSCLC Stage IA, IB, IIA or IIB having surgery	Complete when Surgery Procedure Date is present (denominator = NSCLC cases with TNM Stage IA, IB, IIA or IIB)
PS0-1 NSCLC Stage IA, IB, IIA or IIB	Number of NSCLC cases with Performance Status 0 or 1 and TNM Stage IA, IB, IIA or IIB
% PS0-1 Stage IA, IB, IIA or IIB NSCLC having FEV1 absolute and % predicted	Complete when both FEV1 Percentage and FEV1 Absolute Amount are present (denominator = NSCLC cases with Performance Status 0 or 1 and TNM Stage IA, IB, IIA or IIB)
Number of PS0-1 NSCLC Stage IIIB or IV	Number of NSCLC cases with Performance Status 0 or 1 and TNM Stage IIIB or IV
% PS0-1 Stage IIIB or IV NSCLC having chemotherapy	Complete when Chemotherapy Start Date is present (denominator = NSCLC cases with Performance Status 0 or 1 and TNM Stage IIIB or IV)
Number of histologically confirmed NSCLC	Number of histologically confirmed NSCLC cases
% histologically confirmed NSCLC having surgery	Complete when Surgery Procedure Date is present (denominator = histologically-confirmed NSCLC cases)
Number of pre-treatment NSCLC	Number of pre-treatment NSCLC cases
% pre-treatment NSCLC histology NOS	Percentage of pre-treatment NSCLC cases with Histology NOS (M8046/3) (denominator = pre-treatment NSCLC cases)
Number of patients small cell lung cancer	Number of SCLC cases
% small cell receiving chemotherapy	Complete when Chemotherapy Start Date is present (denominator = SCLC cases)

Footnotes

1) A number of concerns have been raised regarding the current distribution and case number allocation for provider Trusts within Central South Coast Cancer Network (N31)[1] Trusts have agreed to review the baseline data and methodology used, and have agreed in principle to adjust the per Trust case allocation to inform future reports.

2) Data for Barts and The London NHS Trust (RNJ)[2] is incomplete because of technical issues within the trust, and the problem has been identified and will be rectified in the LUCADA database. Performance is not accurately reflected in this report.

3) Data for small cell chemotherapy for Wrightington, Wigan and Leigh NHS Trust (RRF)[3] is incomplete. Performance of this indicator is not accurately reflected in this report.

Key

For per cent of Expected (Case Ascertainment)

- ● Case ascertainment exceeds 75 per cent
- ■ Case ascertainment 50-75 per cent
- ▲ Case ascertainment less than 50 per cent
- ◆ Tertiary Trust standards do not apply

For all other targets

- ● Achieved LAP target set in 2010 report
- ▲ Did not achieve LAP target set in 2010
- ◆ Tertiary Trust. Standards do not apply as most patients are not "first seen" at tertiary trusts.

These trusts often fully participate in the audit and their performance must not be judged from data shown.

Table 2b
Process and clinical outcomes for Scotland (2010 all)

Health board	Actual number (Total)	% of expected	Discussed at MDT (%)	Histo-logical diagnosis (%)	Patient seen by nurse specialist (%)	% having active treatment	% of patients receiving CT before bronchos-copy	% receiving surgery all cases	% receiv-ing radio-therapy	Num-ber of histologi-cally con-firmed NSCLC	% histo-logically con-firmed NSCLC having Surgery	Number of patients small cell lung cancer	% small cell receiving chemo-therapy
SCAN	**1,145**	**88**	**97.0**	**71.5**	**78.8**	**59.5**	**96.7**	**11.1**	**41.0**	**639**	**17.8**	**147**	**60.5**
Borders	90	98	96.7	70.0	96.7	66.7	100.0	12.2	48.9	50	18.0	11	45.5
D & G	109	75	100.0	89.0	86.2	69.7	98.4	12.8	46.8	78	17.9	17	76.5
Fife	288	89	95.8	66.7	55.2	51.0	97.5	8.7	34.7	142	14.8	37	62.2
Lothian	658	89	97.1	71.0	85.4	60.5	95.0	11.7	41.6	369	19.0	82	58.5
WoSCAN	**2,309**	**86**	**94.2**	**79.4**	**86.2**	**63.6**	**90.9**	**11.9**	**37.2**	**1,363**	**17.1**	**379**	**65.4**
Ayrshire & Arran	305	89	98.4	76.1	77.4	57.4	93.6	14.8	38.0	173	18.5	56	50.0
Forth Valley	196	78	98.5	74.5	93.9	66.8	96.3	11.7	33.2	113	16.8	27	63.0
Lanarkshire	450	85	95.3	86.9	94.4	63.8	86.3	15.8	28.2	298	23.2	79	69.6
Clyde	344	89	91.0	79.4	86.6	61.6	82.9	9.9	30.8	187	13.9	61	62.3
North Glasgow	646	92	90.2	79.4	79.7	68.3	92.1	9.9	46.7	374	14.7	108	70.4
South Glasgow	360	81	97.2	75.3	92.5	60.0	97.1	10.6	38.6	211	15.2	47	72.3
Lorn and Island	8	24	75.0	100.0	0.0	75.0	100.0	0.0	62.5	7	0.0	1	0.0
NoSCAN	**973**	**92**	**92.1**	**78.5**	**84.3**	**70.0**	**91.9**	**9.1**	**49.2**	**582**	**12.9**	**135**	**74.8**
Grampian	371	92	86.6	79.0	81.4	78.5	89.0	7.6	61.4	214	9.8	64	75.0
Orkney	0	0											
Shetland	10	167											
Highland	211	90	95.6	84.7	80.8	61.6	93.9	11.4	33.2	159	15.1	23	73.9
Western Isles	18	129											
Tayside	363	92	95.6	74.1	89.5	66.4	93.3	9.4	46.6	209	14.4	48	75.0
Scotland Total	**4,427**	**88**	**94.4**	**77.2**	**83.9**	**63.9**	**92.2**	**11.1**	**40.8**	**2,584**	**16.3**	**661**	**66.3**

Cancer Audit data is collected and collated by NHS Greater Glasgow and Clyde [GG&C] as part of the Service Level Agreement NHS Highland [Argyll & Bute] has in place with NHS GG&C. Cancer Audit data and Case Ascertainment figures relating to patients diagnosed within Argyll and Bute, for the purposes of this report, will be shown separately within WoSCAN's analysis. Future analysis of Argyll and Bute patients will be incorporated into NHS Highland analysis, where appropriate.

Table 2c
Process and clinical outcomes for Northern Ireland (2010 all) - Part I

Code	Actual number	Discussed at MDT (%)	Histological diagnosis (%)	Patient seen by nurse Specialist (%)	Nurse specialist present at diagnosis (%)	% Having active treatment	% of patients receiving CT before bronchos-copy	% receiving surgery all cases	% receiving radiother-apy	% TNM version 6 stage recorded	% TNM version 7 stage recorded
ZT001	319	100.0 ●	76.2 ●	57.5 ▲	n/a	69.6 ●	90.1 ●	13.3	45.1	0.0	100.0
ZT002	162	100.0 ●	82.1 ●	62.3 ▲	n/a	63.0 ●	83.3 ▲	11.7	29.0	0.0	100.0
ZT003	158	98.7 ●	86.1 ●	64.6 ▲	n/a	63.9 ●	86.7 ▲	12.7	35.4	0.0	100.0
ZT004	181	95.5 ●	64.7 ▲	77.9 ▲	n/a	56.9 ▲	67.5 ▲	9.9	22.7	0.0	100.0
ZT005	146	95.9 ●	69.2 ▲	54.8 ▲	n/a	68.5 ●	87.0 ▲	13.0	35.6	0.0	100.0
NI Total	**986**	**98.3** ●	**75.4** ●	**62.8** ▲	**n/a**	**65.1** ●	**83.5** ▲	**12.3**	**35.4**	**0.0**	**100.0**

Table 2c
Process and clinical outcomes for Northern Ireland (2010 all) - Part II

Code	Actual number	Number of NSCLC	% of NSCLC having Surgery	NSCLC Stage IA, IB, IIA or IIB	% of NSCLC Stage IA, IB, IIA or IIB having surgery	PS0-1 NSCLC Stage IA, IB, IIA or IIB	% PS0-1 NSCLC Stage IA, IB, IIA or IIB having FEV1 absolute and % predicted
ZT001	319	282	15.6 ●	71	43.7 ▲	40	95.0 ●
ZT002	162	120	12.5 ▲	26	46.2 ▲	16	87.5 ●
ZT003	158	129	14.7 ●	25	60.0 ●	3	33.3 ▲
ZT004	201	170	11.2 ▲	39	43.6 ▲	19	100.0 ●
ZT005	146	130	12.3 ▲	16	100.0[1] ●	11	81.8 ▲
NI Total	**986**	**831**	**13.6 ▲**	**177**	**51.4 ▲**	**89**	**91.0 ●**

Table 2c (continued)
Process and clinical outcomes for Northern Ireland (2010 all) - Part II

Code	Number of PS0-1 NSCLC Stage IIIB or IV	% PS0-1 Stage IIIB or IV NSCLC having chemotherapy	Number of histologically confirmed NSCLC	% histologically confirmed NSCLC having surgery	Number of pre-treatment NSCLC	% pre-treatment NSCLC histology NOS	Number of patients small cell lung cancer	% small cell receiving chemotherapy
ZT001	60	61.7 ●	206	21.4	206	1.4	27	70.4 ●
ZT002	26	42.3 ▲	92	16.3	93	0.0	29	41.4 ▲
ZT003	5	60.0 ●	107	17.8	106	2.8	23	34.8 ▲
ZT004	23	47.8 ▲	102	18.6	101	0.0	22	59.1 ▲
ZT005	15	26.7 ▲	85	18.8	85	11.8	13	69.2 ●
NI Total	**129**	**51.2 ▲**	**592**	**19.1**	**591**	**2.7**	**114**	**53.5 ▲**

Footnote
1) High percentage may reflect generally lower levels of staging.

Table 2d
Process, nursing, imaging and clinical outcomes for Guernsey (2010 all) - Part I

Code	Actual number	% of expected	Discussed at MDT (%)	Histological diagnosis (%)	Patient seen by nurse Specialist (%)	Nurse specialist present at diagnosis (%)	% Having active treatment	% of patients receiving CT before bronchos-copy	% receiving surgery all cases	% receiving radiotherapy
Guernsey Total	**42**	**116**	**n/a**	**95.2**	**n/a**	**38.1**	**69.0**	**92.0**	**11.9**	**11.9**

Table 2d
Process, nursing, imaging and clinical outcomes for Guernsey (2010 all) - Part II

Code	Actual number	% of expected	Number of NSCLC	% of NSCLC having Surgery	NSCLC Stage IA, IB, IIA or IIB	% of NSCLC Stage IA, IB, IIA or IIB having surgery	PS0-1 NSCLC Stage IA, IB, IIA or IIB	% PS0-1 NSCLC Stage IA, IB, IIA or IIB having FEV1 absolute and % predicted
Guernsey Total	**42**	**116**	**36**	**11.1**	**4**	**50.0**	**n/a**	**n/a**

Table 2d (continued)
Process, nursing, imaging and clinical outcomes for Guernsey (2010 all) - Part II

Code	Number of PS0-1 NSCLC Stage IIIB or IV	% PS0-1 Stage IIIB or IV NSCLC having chemotherapy	Number of histologically confirmed NSCLC	% histologically confirmed NSCLC having surgery	Number of pre-treatment NSCLC	% pre-treatment NSCLC histology NOS	Number of patients small cell lung cancer	% small cell receiving chemotherapy
Guernsey Total	**12**	**83.3**	**34**	**11.8**	**33**	**6.1**	**4**	**75.0**

Indicator	Definition
Actual number	Number of cases with date first seen in year specified
% of expected	Completeness of data in cohort based on Expected Annual Cases in Table 1a of the National Lung Cancer Audit 2009
Number of NSCLC	Number of NSCLC cases
% of NSCLC having Surgery	Complete when Surgery Procedure Date is present (denominator = NSCLC cases)
NSCLC Stage IA, IB, IIA or IIB	Number of NSCLC cases with TNM Stage IA, IB, IIA or IIB
% of NSCLC Stage IA, IB, IIA or IIB having surgery	Complete when Surgery Procedure Date is present (denominator = NSCLC cases with TNM Stage IA, IB, IIA or IIB)
PS0-1 NSCLC Stage IA, IB, IIA or IIB	Number of NSCLC cases with Performance Status 0 or 1 and TNM Stage IA, IB, IIA or IIB
% PS0-1 Stage IA, IB, IIA or IIB NSCLC having FEV1 absolute and % predicted	Complete when both FEV1 Percentage and FEV1 Absolute Amount are present (denominator = NSCLC cases with Performance Status 0 or 1 and TNM Stage IA, IB, IIA or IIB)
Number of PS0-1 NSCLC Stage IIIB or IV	Number of NSCLC cases with Performance Status 0 or 1 and TNM Stage IIIB or IV
% PS0-1 Stage IIIB or IV NSCLC having chemotherapy	Complete when Chemotherapy Start Date is present (denominator = NSCLC cases with Performance Status 0 or 1 and TNM Stage IIIB or IV)
Number of histologically confirmed NSCLC	Number of histologically confirmed NSCLC cases
% histologically confirmed NSCLC having surgery	Complete when Surgery Procedure Date is present (denominator = histologically confirmed NSCLC cases)
Number of pre-treatment NSCLC	Number of pre-treatment NSCLC cases
% pre-treatment NSCLC histology NOS	Percentage of pre-treatment NSCLC cases with histology NOS (M8046/3) (denominator = pre-treatment NSCLC cases)
Number of patients small cell lung cancer	Number of SCLC cases
% small cell receiving chemotherapy	Complete when Chemotherapy Start Date is present (denominator = SCLC cases)

Appendices

Appendix 1: Trust identification for England and Wales

N01	Lancashire and South Cumbria
RTX	University Hospitals of Morecambe Bay NHS Foundation Trust
RXL	Blackpool Teaching Hospitals NHS Foundation Trust
RXN	Lancashire Teaching Hospitals NHS Foundation Trust
RXR	East Lancashire Hospitals NHS Trust

N02	Greater Manchester and Cheshire
RBT	Mid Cheshire Hospitals NHS Foundation Trust
RBV	The Christie NHS Foundation Trust
RJN	East Cheshire NHS Trust
RM2	University Hospital of South Manchester NHS Foundation Trust
RM3	Salford Royal NHS Foundation Trust
RM4	Trafford Healthcare NHS Trust
RMC	Bolton NHS Foundation Trust
RMP	Tameside Hospital NHS Foundation Trust
RRF	Wrightington, Wigan and Leigh NHS Foundation Trust
RW3	Central Manchester University Hospitals NHS Foundation Trust
RW6	Pennine Acute Hospitals NHS Trust
RWJ	Stockport NHS Foundation Trust

N03	Merseyside and Cheshire
RBL	Wirral University Teaching Hospital NHS Foundation Trust
RBN	St Helens and Knowsley Hospitals NHS Trust
RBQ	Liverpool Heart and Chest NHS Foundation Trust
REM	Aintree University Hospitals NHS Foundation Trust
REN	Clatterbridge Centre for Oncology NHS Foundation Trust
RJR	Countess of Chester Hospital NHS Foundation Trust
RQ6	Royal Liverpool and Broadgreen University Hospitals NHS Trust
RVY	Southport and Ormskirk Hospital NHS Trust
RWW	Warrington and Halton Hospitals NHS Foundation Trust

N06	Yorkshire Cancer Network
RAE	Bradford Teaching Hospitals NHS Foundation Trust
RCB	York Teaching Hospital NHS Foundation Trust
RCD	Harrogate and District NHS Foundation Trust
RCF	Airedale NHS Foundation Trust
RR8	Leeds Teaching Hospitals NHS Trust
RWY	Calderdale and Huddersfield NHS Foundation Trust
RXF	Mid Yorkshire Hospitals NHS Trust

N07	Humber and Yorkshire Coast Cancer Network
RCC	Scarborough and North East Yorkshire Healthcare NHS Trust
RJL	Northern Lincolnshire and Goole Hospitals NHS Foundation Trust
RWA	Hull and East Yorkshire Hospitals NHS Trust

N08	North Trent
RFF	Barnsley Hospital NHS Foundation Trust
RFR	The Rotherham NHS Foundation Trust
RFS	Chesterfield Royal Hospital NHS Foundation Trust
RHQ	Sheffield Teaching Hospitals NHS Foundation Trust
RP5	Doncaster and Bassetlaw Hospitals NHS Foundation Trust

N11	Pan Birmingham
RBK	Walsall Healthcare NHS Trust
RR1	Heart of England NHS Foundation Trust
RRK	University Hospitals Birmingham NHS Foundation Trust
RXK	Sandwell and West Birmingham Hospitals NHS Trust

N12	Arden
RJC	South Warwickshire NHS Foundation Trust
RKB	University Hospitals Coventry and Warwickshire NHS Trust
RLT	George Eliot Hospital NHS Trust
RWP01	Worcestershire Acute Hospitals NHS Trust

N20	Mount Vernon Cancer Network
RC9	Luton and Dunstable Hospital NHS Foundation Trust
RWG	West Hertfordshire Hospitals NHS Trust
RWH	East and North Hertfordshire NHS Trust

N21	West London Cancer Network
RAS	The Hillingdon Hospitals NHS Foundation Trust
RC3	Ealing Hospital NHS Trust
RFW	West Middlesex University Hospital NHS Trust
RQM	Chelsea and Westminster Hospital NHS Foundation Trust
RT3	Royal Brompton and Harefield NHS Foundation Trust
RV8	North West London Hospitals NHS Trust
RYJ	Imperial College Healthcare NHS Trust

N22	North London
RAL	Royal Free Hampstead NHS Trust
RAP	North Middlesex University Hospital NHS Trust
RKE	The Whittington Hospital NHS Trust
RQW	The Princess Alexandra Hospital NHS Trust
RRV	University College London Hospitals NHS Foundation Trust
RVL	Barnet and Chase Farm Hospitals NHS Trust

N23	North East London Cancer Network
RF4	Barking, Havering and Redbridge University Hospitals NHS Trust
RGC	Whipps Cross University Hospital NHS Trust
RNH	Newham University Hospital NHS Trust
RNJ	Barts and the London NHS Trust
RQX	Homerton University Hospital NHS Foundation Trust

N24	South East London
RJ1	Guy's and St Thomas' NHS Foundation Trust
RJ2	Lewisham Healthcare NHS Trust
RJZ	King's College Hospital NHS Foundation Trust
RYQ	South London Healthcare NHS Trust

N25	South West London
5LG	Queen Mary's Hospital PCT NHS Trust
RAX	Kingston Hospital NHS Trust
RJ6	Croydon Health Services NHS Trust
RJ7	St George's Healthcare NHS Trust
RPY	The Royal Marsden NHS Foundation Trust
RVR	Epsom and St Helier University Hospitals NHS Trust

N26	Peninsula
RA9	South Devon Healthcare NHS Foundation Trust
RBZ	Northern Devon Healthcare NHS Trust
REF	Royal Cornwall Hospitals NHS Trust
RH8	Royal Devon and Exeter NHS Foundation Trust
RK9	Plymouth Hospitals NHS Trust

N27	Dorset Cancer Network
RBD	Dorset County Hospital NHS Foundation Trust
RD3	Poole Hospital NHS Foundation Trust
RDZ	The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust

N28	Avon Somerset and Wiltshire
RA3	Weston Area Health NHS Trust
RA4	Yeovil District Hospital NHS Foundation Trust
RA7	University Hospitals Bristol NHS Foundation Trust
RBA	Taunton and Somerset NHS Foundation Trust
RD1	Royal United Hospital Bath NHS Trust
RVJ	North Bristol NHS Trust

N29	3 Counties Cancer Network
RLQ	Wye Valley NHS Trust
RTE	Gloucestershire Hospitals NHS Foundation Trust
RWP50	Worcestershire Acute Hospitals NHS Trust

N30	Thames Valley
RD7	Heatherwood and Wexham Park Hospitals NHS Foundation Trust
RD8	Milton Keynes Hospital NHS Foundation Trust
RHW	Royal Berkshire NHS Foundation Trust
RN3	Great Western Hospitals NHS Foundation Trust
RTH	Oxford Radcliffe Hospitals NHS Trust
RXQ	Buckinghamshire Healthcare NHS Trust

N31	Central South Coast
RHM	Southampton University Hospitals NHS Trust
RHU	Portsmouth Hospitals NHS Trust
RN1	Winchester and Eastleigh Healthcare NHS Trust
RN5	Basingstoke and North Hampshire NHS Foundation Trust
RNZ	Salisbury NHS Foundation Trust
RYR	Western Sussex Hospitals NHS Trust
5QT	Isle of Wight NHS PCT

N32	Surrey, West Sussex and Hampshire
RA2	Royal Surrey County Hospital NHS Foundation Trust
RDU	Frimley Park Hospital NHS Foundation Trust
RTK	Ashford and St Peter's Hospitals NHS Foundation Trust
RTP	Surrey and Sussex Healthcare NHS Trust

N33	Sussex
RPL	Worthing and Southlands Hospital NHS Trust
RXH	Brighton and Sussex University Hospitals NHS Trust
RXC	East Sussex Healthcare NHS Trust
RDZ	The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust

N34	Kent and Medway
RN7	Dartford and Gravesham NHS Trust
RPA	Medway NHS Foundation Trust
RVV	East Kent Hospitals University NHS Foundation Trust
RWF	Maidstone and Tunbridge Wells NHS Trust

N35	Greater Midlands
RJD	Mid Staffordshire NHS Foundation Trust
RJE	University Hospital of North Staffordshire NHS Trust
RL4	The Royal Wolverhampton Hospitals NHS Trust
RNA	The Dudley Group of Hospitals NHS Foundation Trust
RWP31	Worcestershire Acute Hospitals NHS Trust
RXW	Shrewsbury and Telford Hospital NHS Trust

N36	North of England Cancer Network
RE9	South Tyneside NHS Foundation Trust
RLN	City Hospitals Sunderland NHS Foundation Trust
RNL	North Cumbria University Hospitals NHS Trust
RR7	Gateshead Health NHS Foundation Trust
RTD	The Newcastle Upon Tyne Hospitals NHS Foundation Trust
RTF	Northumbria Healthcare NHS Foundation Trust
RTR	South Tees Hospitals NHS Foundation Trust
RVW	North Tees and Hartlepool NHS Foundation Trust
RXP	County Durham and Darlington NHS Foundation Trust

N37	Anglia Cancer Network
RC1	Bedford Hospital NHS Trust
RCX	The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust
RGM	Papworth Hospital NHS Foundation Trust
RGN	Peterborough and Stamford Hospitals NHS Foundation Trust
RGP	James Paget University Hospitals NHS Foundation Trust
RGQ	Ipswich Hospital NHS Trust
RGR	West Suffolk Hospitals NHS Trust
RGT	Cambridge University Hospitals NHS Foundation Trust
RM1	Norfolk and Norwich University Hospital NHS Foundation Trust
RQQ	Hinchingbrooke Health Care NHS Trust

N38	Essex Cancer Network
RAJ	Southend University Hospital NHS Foundation Trust
RDD	Basildon and Thurrock University Hospitals NHS Foundation Trust
RDE	Colchester Hospital University NHS Foundation Trust
RQ8	Mid Essex Hospital Services NHS Trust

N39	East Midland Cancer Network
RK5	Sherwood Forest Hospitals NHS Foundation Trust
RWD	United Lincolnshire Hospitals NHS Trust
RX1	Nottingham University Hospitals NHS Trust
RJF	Burton Hospitals NHS Foundation Trust
RTG	Derby Hospitals NHS Foundation Trust
RNQ	Kettering General Hospital NHS Foundation Trust
RNS	Northampton General Hospital NHS Trust
RWE	University Hospitals of Leicester NHS Trust

	Welsh Cancer Network
7A2AJ	Bronglais General Hospital
7A1A1	Glan Clwyd General Hospital
7A4C1	Llandough Hospital
7A3C7	Morriston Hospital
7A3CJ	Neath Port Talbot Hospital
7A6AM	Nevill Hall Hospital
7A5B3	Prince Charles Hospital
7A2AL	Prince Philip Hospital
7A3B7	Princess Of Wales Hospital
7A5B1	Royal Glamorgan Hospital
7A6AR	Royal Gwent Hospital
7A3C4	Singleton Hospital
7A4BV	University Hospital Of Wales
7A2AG	West Wales General Hospital
7A2BL	Withybush General Hospital
7A1AU	Ysbyty Gwynedd
7A1A4	Ysbyty Maelor Wrexham

	Northern Ireland Cancer Network
ZT001	Belfast Health & Social Care Trust
ZT002	Northern Health & Social Care Trust
ZT003	Southern Health & Social Care Trust
ZT004	South-Eastern Health & Social Care Trust
ZT005	Western Health & Social Care Trust

Appendix 2: Local Action Plan

Recommendation	Achieved Y/N/P/NK	Planned Action	Suggested Actions	Suggested Responsibility	Date plan actioned	Date issue resolved
Data Completeness and Quality						
The trust participates in this national audit			Contact local Cancer Network for audit Advice. Contact CASU Lung Cancer audit Project Manager (roz.stanley@ic.nhs.uk) Visit www.ic.nhs.uk/services/national-clinical-audit-support-programme-ncasp for information. Obtain read and disseminate the Lung Cancer Audit Annual Report	Cancer Manager / Governance Lead		
Data on all patients diagnosed with either lung cancer or mesothelioma are submitted to the audit			Use MDT meetings to capture all cases discussed. Try to record cases in real time or near real time. Liaise with pathology departments to correlate cases. Work with IT department to set up CSV file upload facility if information is collected on a third party system or identify resources to input data directly	MDT Chair		
All relevant data fields are completed for each patient			Use proforma for data collection at MDT. Identify key person to QA data prior to submission. Data imputers understand clinical implications of data. Map and allocate responsibility along patient pathway. Agree protocols and submission routes for patients that are treated across different organisations	Data Co-ordinator / Cancer Manager / Network Manager		
Key data fields including stage and performance status should be completed in at least 85 per cent and in at least 95 per cent with respect to the MDT field			Refer to the documentation on the National Lung Cancer Audit Website and ensure that key fields are completed for all relevant cases. Assist MDT co-ordinator by chair ensuring that stage, performance status and other key fields are discussed and recorded for each patient	MDT chair, Data Co-ordinator / Cancer Manager/ Network Manager		
FEV[1] absolute and per cent predicted for stage I and II NSCLC patients with PS 0 or 1 should be recorded in at least 85 per cent						
Process of Care						
Over 95 per cent of patients submitted to the audit are discussed at an MDT			Liaise with cancer waiting times team to identify lung cancer referrals. Liaise with radiology department to identify all imaging suspicious of lung cancer or mesothelioma. Liaise with pathology department to identify cases	MDT chair, Lung cancer clinical lead		
The Histological Confirmation Rate should be at least 75 per cent To be reviewed in light of case-mix adjusted odds ratio			This result should be interpreted in conjunction with the case-mix adjusted odds ratio, which might better reflect whether the organisation is an outlier. Ensure all histological diagnoses are submitted to the audit. Liaise with pathology department to identify cases. Review clinical diagnoses and diagnostics protocols if HCR is below optimum	MDT chair, Lung cancer clinical lead		
The proportion of patients receiving CT prior to bronchoscopy should exceed 90 per cent			Ensure that all CT / bronchoscopy data is submitted to the audit. Review diagnostics protocols if rate is below optimum	MDT chair, Lung cancer clinical lead, Radiologists		

Recommendation	Achieved Y/N/P/NK	Planned Action	Suggested Actions	Suggested Responsibility	Date plan actioned	Date issue resolves
Process of Care (continued)						
Over 80 per cent of patients are seen by a lung cancer specialist nurse			Review the specialist nurse service, ensuring all nursing posts are staffed and that clear referral pathways exist	MDT chair, Lung cancer clinical lead, specialist nurse		
Over 80 per cent of patients have a lung cancer specialist nurse present at the time of diagnosis			Review the specialist nurse service, allocate extra nursing support alongside lung cancer clinics	MDT chair, Lung cancer clinical lead, specialist nurse		
Co-morbidity that prevents a patient receiving treatment of choice should be recorded for all relevant cases			Ensure that all relevant co-morbidity data is discussed at MDT, and ensure that cases where co-morbidity prevents treatment of choice are submitted to the audit. It is important that the collected data adheres to the definitions in the LUCADA data manual.	MDT chair, Lung cancer clinical lead, specialist nurse		
PET Scan dates should be recorded for all relevant cases			Ensure that all PET data is captured at MDT submitted to the audit	MDT chair, Lung cancer clinical lead, specialist nurse		
Clinical Outcomes						
Surgical resection rates below 14 per cent for all patients excluding small cell lung cancer or mesothelioma must be reviewed To be reviewed in light of case-mix adjusted odds ratio			This result should be interpreted in conjunction with the case-mix adjusted odds ratio, which might better reflect whether the organisation is an outlier. Ensure that all surgical resections are submitted to the audit. If data is complete then review treatment policies for early stage lung cancer in patients with good performance status. Ensure that thoracic surgeon attends MDT meetings	MDT chair, Lung cancer clinical lead, thoracic surgeons		
Surgical resection rates for patients for all patients excluding small cell lung cancer or mesothelioma with stage I or II disease below 52 per cent must be reviewed			This result should be interpreted in conjunction with the case-mix adjusted odds ratio, which might better reflect whether the organisation is an outlier. Ensure that all surgical resections are submitted to the audit. If data is complete then review treatment policies for early stage lung cancer in patients with good performance status. Ensure that thoracic surgeon attends MDT meetings	MDT chair, Lung cancer clinical lead, thoracic surgeons		
Active anti-cancer treatment rates below 60 per cent should be reviewed To be reviewed in light of case-mix adjusted odds ratio			This result should be interpreted in conjunction with the case-mix adjusted odds ratio, which might better reflect whether the organisation is an outlier. Ensure that all treatments are submitted to the audit. Review treatment policies for lung cancer patients	MDT chair, Lung cancer clinical lead. MDT members		
Chemotherapy rates for small cell lung cancer below 65 per cent should be reviewed To be reviewed in light of case-mix adjusted odds ratio			This result should be interpreted in conjunction with the case-mix adjusted odds ratio, which might better reflect whether the organisation is an outlier. Ensure that all treatments are submitted to the audit. Review treatment policies for small cell lung cancer patients	MDT chair, Lung cancer clinical lead. MDT members		
Chemotherapy rates for patients of PS 0-1 with advanced stage NSCLC IIIB/ IV below 55 per cent should be reviewed To be reviewed in light of case-mix adjusted odds ratio			This result should be interpreted in conjunction with the case-mix adjusted odds ratio, which might better reflect whether the organisation is an outlier. Ensure that all treatments are submitted to the audit. Review treatment policies for non small cell lung cancer patients with advanced stage	MDT chair, Lung cancer clinical lead. MDT members		
Low median survival, as demonstrated by a case-mix adjusted hazard ratio significantly below the baseline, should be investigated.			Ensure that all relevant data has been submitted to the audit. Identify areas where audit standards have not been met or where CMA demonstrates the trust to be an outlier and review	MDT chair, Lung cancer clinical lead. MDT members		

Appendix 3: Glossary

Anti-cancer treatment
To cure or control cancer progression

Benchmarking
A method of comparing processes and outcomes against standards

Cancer Network
A system within the NHS to organise the integrated care of cancer patients across a region

Case ascertainment
Number of cases recorded as a proportion of those expected

Case-mix
A means of classifying patients for comparing quality of care

Case-mix adjusted
Performance and outcome data corrected for various factors including the age, social deprivation, extent of disease and fitness of the populations under study

Chemotherapy
Drugs used in the treatment of cancer

Cytological
From the study of cells

Diagnosis
Confirming the presence of the disease

Histological
From the study of tissues

Interquartile range
The range of a particular variable excluding the highest quarter and lowest quarter of the values recorded

MDT
Multi-disciplinary team

Mesothelioma
Cancer of the lining of the lung caused by asbestos

Network
See 'Cancer Network'

NLCA
National Lung Cancer Audit

Non-small cell carcinoma
A group of lung cancer including squamous carcinoma and adenocarcinoma

NSCLC
Non-small cell lung cancer

Performance Status
A systematic method of recording the ability of an individual to undertake the tasks of normal daily life compared with that of a normal person

Radiotherapy
Cancer treatment using radiation

SCLC
Small cell lung cancer (small cell carcinoma)

Secondary care
Care provided by a hospital

Small cell lung cancer
Type of neuroendocrine lung cancer strongly associated with smoking

Staging / stage
The anatomical extent of a cancer

Surgical resection
An operation to remove abnormal tissues or organs

Thoracic surgeon
Specialist surgeon who operates on the chest and lungs

Notes

Notes

The NHS Information Centre for health and social care (The NHS IC) is working to make information more relevant and accessible to the public, regulators, health and social care professionals and policy makers, leading to improvements in knowledge and efficiency. The NHS IC is a special NHS health authority that collects analyses and distributes data to reduce the burden on frontline staff, releasing more time for direct care.

Document reference: IC22090211

Need to know more?

T. 0845 300 6016
E. enquiries@ic.nhs.uk
www.ic.nhs.uk

The NHS Information Centre
for health and social care
1 Trevelyan Square
Boar Lane
Leeds
LS1 6AE